British Journal of Anaesthesia, 133 (2): 380-399 (2024)

doi: 10.1016/j.bja.2024.04.044 Advance Access Publication Date: 28 May 2024 Review Article

REGIONAL ANAESTHESIA

Impact of spinal or epidural anaesthesia on perioperative outcomes in adult noncardiac surgery: a narrative review of recent evidence

David W. Hewson^{1,2,*}, Tiffany R. Tedore³ and Jonathan G. Hardman^{1,2}

¹Department of Anaesthesia and Critical Care, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK, ²Academic Unit of Injury, Recovery and Inflammation Sciences, School of Medicine, University of Nottingham, Nottingham, UK and ³Department of Anesthesiology, Weill Cornell Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA

*Corresponding author. E-mail: david.hewson@nottingham.ac.uk, X@davidwhewson

Summary

Spinal and epidural anaesthesia and analgesia are important anaesthetic techniques, familiar to all anaesthetists and applied to patients undergoing a range of surgical procedures. Although the immediate effects of a well-conducted neuraxial technique on nociceptive and sympathetic pathways are readily observable in clinical practice, the impact of such techniques on patient-centred perioperative outcomes remains an area of uncertainty and active research. The aim of this review is to present a narrative synthesis of contemporary clinical science on this topic from the most recent 5-year period and summarise the foundational scholarship upon which this research was based. We searched electronic databases for primary research, secondary research, opinion pieces, and guidelines reporting the relationship between neuraxial procedures and standardised perioperative outcomes over the period 2018-2023. Returned citation lists were examined seeking additional studies to contextualise our narrative synthesis of results. Articles were retrieved encompassing the following outcome domains: patient comfort, renal, sepsis and infection, postoperative cancer, cardiovascular, and pulmonary and mortality outcomes. Convincing evidence of the beneficial effect of epidural analgesia on patient comfort after major open thoracoabdominal surgery outcomes was identified. Recent evidence of benefit in the prevention of pulmonary complications and mortality was identified. Despite mechanistic plausibility and supportive observational evidence, there is less certain experimental evidence to support a role for neuraxial techniques impacting on other outcome domains. Evidence of positive impact of neuraxial techniques is best established for the domains of patient comfort, pulmonary complications, and mortality, particularly in the setting of major open thoracoabdominal surgery. Recent evidence does not strongly support a significant impact of neuraxial techniques on cancer, renal, infection, or cardiovascular outcomes after noncardiac surgery in most patient groups.

Keywords: epidural anaesthesia; general anaesthesia; patient-reported outcome measures; perioperative care; spinal anaesthesia

Received: 20 February 2024; Accepted: 30 April 2024

© 2024 The Author(s). Published by Elsevier Ltd on behalf of British Journal of Anaesthesia. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).

For Permissions, please email: permissions@elsevier.com

Editor's key points

- Spinal and epidural blocks remain effective techniques in anaesthesia and acute pain management, even after the advent of minimally invasive surgery, fast-track programmes and fascial plane blocks.
- This narrative review summarises recent (2018-2023) evidence about patient-centred outcomes associated with spinal and epidural anaesthesia and analgesia.
- A beneficial effect of epidural analgesia on pain scores after major open thoracic and abdominal surgery outcomes was identified.
- The evidence of benefit in the prevention of cardiovascular, pulmonary, renal, infection, cancer, cognitive and morality outcomes was less consistent.
- Future clinical trials and subsequent meta-analyses on neuraxial techniques will benefit from more structured inclusion of standardised patient outcomes.

Subarachnoid and epidural anaesthesia were first described by August Bier in 1898 and Fidel Pagés in 1921, respectively.¹ A century of scientific enquiry examining the anatomy, physiology, and pharmacology associated with neuraxial block, together with refinement of insertional techniques and procedural equipment, has given anaesthetists an excellent appreciation of their potential role, conduct, and limitations. Research delivered at a national scale has carefully defined the rare but potentially catastrophic complications of these procedures, allowing clinicians and patients to select specific techniques with informed discussion of material risk and benefit.² The manifest anaesthetic effects, analgesic effects, or both of appropriately conducted epidural and spinal anaesthesia are readily observable in clinical practice and therefore these techniques have an important place in the armamentarium of many clinicians. Addressing what impact, if any, neuraxial block has on patient-centred outcomes beyond the immediate anaesthetic/analgesic effect accounts for a significant body of ongoing perioperative research, and this interest has coincided with new consensus-derived standardised definitions of perioperative outcome measures.³ Such outcome measures have been proposed as having primary importance to patients, clinicians, and health service providers.⁴ Careful assessment of the relationship between neuraxial techniques and standardised outcome measures will assist clinicians and patients in shared decision-making before surgery. Benefits often ascribed to neuraxial techniques (e.g. improved postoperative respiratory function), are increasingly debated as minimally invasive surgical approaches replace traditional, open surgery.

To summarise, appraise, and synthesise the most recent international evidence relating to the impact of spinal and epidural anaesthesia and analgesia on perioperative outcomes, we conducted a review of the literature published within the past 5 years, accompanied by narrative synthesis of results. Our aim is to describe the current state of evidence relating to the clinical effectiveness of neuraxial techniques applied to adult patients undergoing noncardiac surgery and to place this contemporary research in the context of preceding scholarship.

Methods

In this review, we sought to identify contemporary articles describing spinal or epidural anaesthesia. After a literature search, we used narrative synthesis to summarise this contemporary research (defined as published within the past 5 years), alongside the historical studies upon which this science is based.

Eligibility criteria

Inclusion criteria for studies were: (1) primary (observational or non-experimental studies, prospective trials) or secondary research (systematic reviews with or without meta-analyses), opinion pieces (editorial), or consensus-derived practice guidelines; (2) addressing perioperative outcomes from spinal or epidural analgesia or anaesthesia, either as single-shot block or catheter-based techniques, alone or in combination with general anaesthesia; (3) reported in non-pregnant adult (age \geq 18 yr) human subjects undergoing noncardiac surgery; and (4) available in English language or with English language translation.


Exclusion criteria were primary study addressing the basic science relating to anatomy, procedural conduct, physiological consequences, or pharmacology of neuraxial block.

Search strategy

Applying the principles described by Bramer and colleagues,⁵ we devised a search strategy and performed a search of MEDLINE and EMBASE for titles, abstracts, and keyword medical subject headings (MeSH) terms from electronic journal databases using the OVID platform between January 1, 2018 and September 1, 2023. Forty key general and relevant specialty journal databases were included in the search (Supplementary material). A grey literature search was conducted on the ProQuest thesis and dissertation platform. A supplementary search of Google Scholar was performed using the same date range. To minimise bias in the return of Google Scholar search results, that search was conducted using private web-browsing mode. The first 200 Google Scholar records were reviewed for inclusion. The following search terms were applied to titles and abstracts: spinal, intrathecal, subarachnoid, epidural, extradural, caudal, analgesia, anaesthesia. Terms were applied with spelling wildcards and Boolean operators (Supplementary material). After automated exclusion of duplicate entries, the titles and abstracts of returned studies were screened to determine whether they addressed perioperative outcome measures and should proceed to full-text review. Both initial screening and full-text review were performed by two authors (DWH and JGH), with the third author (TT) available to adjudicate if required. Articles addressing anatomical, procedural, physiological, or pharmacological considerations without consideration of perioperative outcome measures were excluded. The reference lists of studies that were selected for full-text review were screened for additional articles not identified via the above search strategy.

Outcome measures of interest

Identified articles were assessed for their reporting of outcome measures established by the Standardised Endpoints in Perioperative Medicine (StEP) initiative³ according to the following



domains: patient comfort and patient-centred outcomes^{6,7}; infection and sepsis⁸; postoperative cancer outcomes⁹; renal endpoints¹⁰; cardiovascular outcomes¹¹; pulmonary complications¹²; and mortality, morbidity, and organ failure.¹³ Table 1 provides a description of the identified StEP domains and core outcomes.

Results

A flow diagram of search results is shown in Figure 1. Our search strategy included caudal anaesthesia, as a type of epidural technique; however, we identified no relevant recent publications addressing the relationship between adult caudal anaesthesia or analgesia and StEP-advocated perioperative outcomes. A summary of contemporary articles identified by our search strategy and included in narrative discussion is provided in Table 2.

Discussion

Patient comfort and patient-centred outcomes

Orthopaedic and ambulatory surgery

Large, retrospective studies and consensus reviews published since 2018 have established the role of neuraxial anaesthesia for lower limb joint arthroplasty.^{14,15} Reported patient-centred benefits of neuraxial anaesthesia compared with general anaesthesia include decreased length of hospital stay, postoperative pain, opioid consumption, and incidence of postoperative nausea and vomiting (PONV). Two systematic review and meta-analyses (SRMAs) published in the preceding 5 years have reported significant analgesic benefit of intrathecal opioid for arthroplasty surgery, but at the reported cost of higher rates of nausea and vomiting¹⁶ and pruritis.¹⁷ Both reviews conclude that additional research is required to explore optimal intrathecal opioid dosing. High-quality evidence reported in 2021 demonstrates that intrathecal morphine (in common with fentanyl and diamorphine) is no more likely to cause respiratory depression than controls who received no intrathecal opioid.¹⁶

Several recent large RCTs have attempted to determine whether neuraxial anaesthesia has benefits compared with general anaesthesia for hip fracture surgery.^{18–20} One of the most prominent trials, Regional versus General Anesthesia for Promoting Independence after Hip Fracture (REGAIN), included patient-centred outcomes such as the inability to walk without human assistance at 60 days, discharge disposition, and worsened walking ability.¹⁸ There was no difference between spinal and general anaesthesia in the inability to walk independently at 60 days (15.2% and 14.4%, respectively; relative risk [RR] 1.05, 95% confidence interval [CI] 0.82-1.36), discharge disposition (home, long-term care facility, hospice, rehabilitation), or worsened walking ability. The pragmatic design of REGAIN (e.g. purposefully broad eligibility criteria and the non-protocolisation of intervention and control arm treatments) replicates 'real-world' practice, but nevertheless clinical circumstances (e.g. the presence of active respiratory infection, or the skill of an individual anaesthetic practitioner in a particular technique) may mean one anaesthetic method is preferred over another in specific circumstances.

Patient-centred outcomes Quality of recovery from anaesthesia and surgery Time to gastrointestinal recovery Time to pastrointestinal recovery Time to notilisation Sieep disturbance 12 months after surgery plus or minus 6-month assessment and use of recover antiemetic medication Quality of Recovery score or measurement information system (ROMMS) derived five tern Likert scale disters and use of functional status Patient-centred outcomes Health-related quality of life 12 months after surgery plus or minus 6-month assessment Patient-reported outcome wersion 2.0, 1.2 question versi outcomes Patient satisfaction Within 24 h of surgery to a maximum of 48 h Dascharge destination* Infection and sepsis Fever At 30 days after surgery dus woredings within a 12-h period Discharge destination* Respiratory infectious complication Clostralum difficie coltis/infectiou complication Within 30 days of surgery Center for Disease Control definition Patient satisfaction measure* Within 30 days of surgery Center for Disease Control definition Respiratory infectious complication Clostralum difficie coltis/infection Within 30 days of surgery Center for Disease Control definition Idemiticion of pathogenic organism from tissue or fluid Surgical is infection (SS): superficial, deep, and/or organ/ surgery Within 30 days of surgery Third International Consensus Definitions for Sepsis and Sep Shock (EUSIS-3) Pestoperative cancer outcomes Cancer health-related quality of life At 90 days after surgery Third International Conse	StEP domain	Sub-domains	Recommended time point(s) for assessments	Recommended assessment tool(s)/definition or other comments
Nausea and vormiting0-6 h; 6-24 h and overallIncidence or nausea and vormiting and use of rescue antiemetic medicationQuality of recovery from anaesthesia and surgery Time to mobilisationQuality of Recovery: 55 scale minus 6-month assessmentIncidence or nausea and vormitic medicationPatient-centred outcomesHealth-related quality of life medication12 months after surgery plus or minus 6-month assessmentPatient-reported outcome messurement information minus 6-month assessmentPatient-centred outcomesHealth-related quality of life minus 6-month assessmentVord Health organization Disability Assessment 5ched version 2, 0, 2, question tests minus 4- h of surgery to a messurement sched version 2, 0, 2, question tests messureInfection and sepsisFeverWithin 24 h of surgery on minus 4-1 y after surgery Within 30 days of surgeryDischarge destination* Bauer patient astisfaction messure*Infection and sepsisFeverWithin 30 days of surgery wor radings within 12-h patientCenter for Disease Control definitionNeurological infectious complicationWithin 30 days of surgery wor analyse within 30 days of surgeryCenter for Disease Control definitionIndentification of pathogenic superial surgical site infection (SS): surgical site infection (SS): surgical site infection (SS): surgical site infection (SS): surgers surgersWithin 30 days of surgery within 30 days of surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SPSIS-3)Pestoperative cancer outcomesCancer health-related quality of life Days alive and out of hospital <br< td=""><td>Patient comfort</td><td></td><td></td><td>11-point numeric rating scale</td></br<>	Patient comfort			11-point numeric rating scale
Patient-centred outcomes Health-related quality of life messurement of functional status 12 months after surgery plus or minus 6-month assessment School minus 6-month assessment School minus 6-month assessment School Disability Assessment School Core temperature 28, 5°C Core temperature 28, 5°C Disability Assessment School Core temperature 28, 5		Nausea and vomiting 0–6 h; 6–24 h and overa		Incidence of nausea and vomitin and use of rescue antiemetic medication
Patient-centred outcomes Health-related quality of life 12 months after surgery plus or minus 6-month assessment Patient reported outcome measurement information surgery plus or minus 6-month assessment Patient reported outcome measurement information surgery plus or minus 4 or angery plus or minus 4 or after surgery 10 poss alive and out of hospital Discharge destination* Bauer patient satisfaction measurement of functional status Infection and sepsis Fever More than 24 h after surgery an maximum of 48 h More than 24 h after surgery an measurement wor cadings within a 12-h period Discharge destination* Bauer patient satisfaction measure Neurological infectious complication Within 30 days of surgery urinary system infectious Within 30 days of surgery within 30 days of surgery complication Center for Disease Control definition Infection and sepsis Endometritis Within 30 days of surgery urinary system infectious complication Within 30 days of surgery within 30 days of surgery complication of pathogenic omplication of pathogenic omplication surgery for deep and/or organ/space SI in apecific aurgical subserifies including breast, cardiac, spinal surgery Third International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3) Postoperative cancer outcomes Cancer health-related quality of life Days alive and out of hospinal The to tumour progression or death from Juscession or death from Juscession or death from Juscession or death from Juscession or death from specific. cancer therapy </td <td></td> <td></td> <td></td> <td>Quality of Recovery score or</td>				Quality of Recovery score or
Sileg disturbance Patient -centred outcomes Health-related quality of life 12 months after surgery plus or minus 6-month assessment Model minus 6-month assessment Model minus 6-month assessment Model Neasurement of functional status Health-related quality of life 12 months after surgery plus or minus 61 yr after surgery Patient satisfaction Health-related quality of life Health-related quality o		Time to gastrointestinal recovery		
Patient-centred outcomes Health-related quality of life 12 months after surgery plus or minus 6-month assessment Life-impact measures Life-impact measures Life-impact measures Life-impact measures Life-impact measures Life-impact measures Patient satisfaction Patient satisfaction Measurement of functional status Life-impact measures Patient satisfaction Measurement of surgery to a maximum of 48 h More than 24 h after surgery Mithin 30 days of surgery Mithin 30 days of surgery Center for Disease Control definition Meurological infectious complication Within 30 days of surgery Center for Disease Control definition Control functionis (SD): Superficial, deep, and/or organ/ space Postoperative cancer outcomes Sepsis Postoperative Cancer health-related quality of life Cancer health-related quality of life Cancer specific survival Cancer specific survival Canc				measurement information
Patient-centred outcomes Health-related quality of life 12 months after surgery plus or minus 6-month assessment EuroQol 5 dimension (EQ-5D-51 World Health Organization Disability Assessment 5 ched version 2.0, 12-question version Days after surgery plus or minus at 1 yr after surgery plus or maximum of 48.h EuroQol 5 dimension (EQ-5D-51 World Health Organization Disability Assessment 5 ched version 2.0, 12-question version Days after surgery plus or maximum of 48.h EuroQol 5 dimension (EQ-5D-51 World Health Organization Disability Assessment 5 ched version 2.0, 12-question versi- Days after surgery plus on dout of hospital maximum of 48.h EuroQol 5 dimension (EQ-5D-51 World Health Organization Disability Assessment 5 ched version 2.0, 12-question versi- Days after surgery plus on dout of hospital measures EuroQol 5 dimension (EQ-5D-51 World Health Organization Disability Assessment 5 ched version 2.0, 12-question versi- parity and plus of surgery plus on definition EuroQol 5 dimension (EQ-5D-51 World Health Organization measures Infection and sepsis Fever Within 30 days of surgery on minus within 30 days of surgery or dep and/or organ/space 5 in specific organ/space 5 in specific surgery plus surgery space Center for Disease Control definition Infection (SD): Within 30 days of surgery for deep and/or organ/space 5 in specific surgery plus surgery Third International Consensus Definitions for Sepsis and Sep Shock (EPSIS-3) Postoperative cancer outcomer Cancer health-related quality of life instrument Third International Consensus Definitions for Sepsis and Sep Shock (EPSIS-13) Postoperative cancer				system (PROMIS)-derived five- item Likert scale
Disability Assessment Schedu wersion versi Days alive and out of hospital minus at 1 yr after surgery plus or minus at 1 yr after surgery Patient satisfactionDisability Assessment Schedu version versi Days alive and out of hospital Discharge destination* Bauer patient satisfaction measure* Core temperature >38.5°CInfection and sepsisFeverMore than 24 h after surgery at maximum of 48 h of surgery to a maximum of 48 h of surgeryDisability Assessment Schedu version versi Days alive and out of hospital measure* Core temperature >38.5°CInfection and sepsisFeverMore than 24 h after surgery at more than 24 h after surgery Within 30 days of surgeryCenter for Disease Control definition Conter for Disease Control definitionUrinary system infectious complication Clostridium difficile colitis/infection surger/sing in from tissue or fluid surgical site infection (SSI): super ficial, deep, and/or organ/ spaceWithin 30 days of surgery for deep and/or organ/space SSI in specific surgical subsets including breast, cardiac, spinal surgeryBased on Center for Disease Control definitionPostoperative cancer outcomesCancer health-related quality of life ass alive and out of hospital Time to tumour progressionAt 90 days after surgery At 90 days after surgery Time elapsed between treatme maximument*Postoperative cancer outcomesCancer-specific survivalAt 90 days after surgery and at a death from any cause three algased between treatme and death from any cause three algased between treatme and death from any causePostoperative cancer outcomesCancer-specific survivalAt 90 days after surgery <b< td=""><td></td><td>Health-related quality of life</td><td></td><td>EuroQol 5 dimension (EQ-5D-5L)</td></b<>		Health-related quality of life		EuroQol 5 dimension (EQ-5D-5L)
Life-impact measures At 30 days after surgery plus or minus at 1 yr after surgery between treatmean Days alive and out of hospital Infection and sepsis Patient satisfaction Within 24 h of surgery to a measure Discharge destination* Bauer patient satisfaction measure Discharge destination* Bauer patient satisfaction definition Virinary system infectious complication Within 30 days of surgery organism from tissue or fluid Surgical site infection (SSI): superficial, deep, and/or organ/space SSI in specific surgical subsets including breast, cardiac, spinal surgery Discharge destination* Center for Disease Control definition Postoperative cancer outcomes Sepsis Sepsis and Sep Shock (SEPSIS-3) Third International Consensus Definitons for Sepsis and Sep Shock (SEPSIS-3) Postoperative cancer outcomes Cancer health-related quality of life At 90 days after surgery Thine elapsed b		Measurement of functional status	Disability Assessment Schedul	
Patient satisfactionWithin 24 h of surgery to a maximum of 48 hDischarge destination* measure*Infection and sepsisFeverMore than 24 h after surgery and two readings within a 12-h periodCenter for Disease Control definitionRespiratory infectious complicationWithin 30 days of surgeryCenter for Disease Control definitionUrinary system infectious complicationWithin 30 days of surgeryCenter for Disease Control definitionUrinary system infectious complicationWithin 30 days of surgeryCenter for Disease Control definitionIdentification of pathogenic organism from tissue or fluid Surgical site infection (SSI): spaceWithin 30 days of surgery Within 30 days of surgery plus or musu within 90 days of surgery within 30 days of surgery within 30 days of surgeryCenter for Disease Control definitionPostoperative cancer outcomesSepsisWithin 30 days of surgery spaceThird International Consensus Definitional Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Third International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life Days alive and out of hospital Time to tumour progressionAt 90 days after surgery Time elapsed between treatme and death from any causePostoperative cancer -specific survivalCancer-specific survivalAt 90 days after surgery Time elapsed between treatme an death from any cause		Life-impact measures		
Infection and sepsis Fever More than 24 h after surgery an two readings within a 12-h period Core temperature >38.5°C Respiratory infectious complication Within 30 days of surgery Center for Disease Control definition Neurological infectious complication Within 30 days of surgery Center for Disease Control definition Urinary system infectious complication Within 30 days of surgery Center for Disease Control definition Clostridium difficile colitis/infection Within 30 days of surgery Center for Disease Control definition Identification of pathogenic organism from tissue or fluid Surgical site infection (SSI): superficial, deep, and/or organ/ space Within 30 days of surgery for deep and/or organ/space SSI in specific surgery Center for Disease Control definitions Sepsis Sepsis Within 30 days of surgery Third International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3) Postoperative cancer outcomes Cancer health-related quality of life Ya 00 days after surgery Third International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3) Postoperative cancer outcomes Cancer nealth-related quality of life Ya 00 days after surgery Time elapsed between treatme and tumour progression or death from any cause Postoperative cancer outcomes Cancer -specific survival At 90 days after surgery Time elapsed between treatme and dumour progression or death from any cause Disease-free survival Ti		Patient satisfaction	, , , , , , , , , , , , , , , , , , , ,	
Respiratory infectious complicationWithin 30 days of surgery definitionCenter for Disease Control definitionNeurological infectious complicationWithin 30 days of surgeryCenter for Disease Control definitionUrinary system infectious complicationWithin 30 days of surgeryCenter for Disease Control definitionIdentificationClostridium difficile colitis/infectionWithin 30 days of surgeryCenter for Disease Control definitionEndometritisWithin 30 days of surgeryBased on Center for Disease Control definitionIdentification of pathogenic organism from tissue or fluidWithin 30 days of surgeryBased on Center for Disease Control definitionSurgical site infection (SSI) spaceWithin 30 days of surgery plus or minus within 90 days of surgeryCenter for Disease Control definitionSepsisWithin 30 days of surgeryCenter for Disease Control definitionSepsisSepsisWithin 30 days of surgeryCenter for Disease Control definitionSepsisSeptic shockWithin 30 days of surgeryCenter for Disease Control definitionDefinitions for Sepsis and Sep Shock (SEPSIS-3)Shock (SEPSIS-3)Third International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life instrumentAt 90 days after surgeryTime elapsed between treatme and tumour progression or death from tumour or cancer therapyPostoperative cancer outcomesCancer-specific survivalAt 90 days after surgeryTime elapsed between treatme and tu	Infection and sepsis	Fever	More than 24 h after surgery and two readings within a 12-h	
Neurological infectious complicationWithin 30 days of surgery (Center for Disease Control definition (Center for Disease Control definitionUrinary system infectious complicationWithin 30 days of surgery (Center for Disease Control definitionClostridium difficile colitis/infectionWithin 30 days of surgery (Center for Disease Control definitionEndometritisWithin 30 days of surgery (Center for Disease Control definitionIdentification of pathogenic organism from tissue or fluid Surgical site infection (SSI): spaceWithin 30 days of surgery minus within 90 days of surgery in specific surgical subsets in specific surgical subsets including breast, cardiac, spinal surgeryCenter for Disease Control definitionPostoperative cancer outcomesCenter for Disease Control definitionCenter for Disease Control definitionPostoperative cancer outcomesCenter for Disease Control definitionCenter for Disease Control definitionPostoperative cancer outcomesCenter for Disease Control definitionCenter for Disease Control definitionPostoperative cancer outcomesCenter for Disease Control for deep and/or organ/space SI inspecific surgical subsets including breast, cardiac, spinal surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life instrument'Ya cancer related quality of life instrument'Disease-free survivalAt 90 days after surgery inter to numour progression or death from any cause and tumour progression or death from any cause an		Respiratory infectious complication		
complicationdefinitionClostridium difficile colitis/infectionWithin 30 days of surgeryCenter for Disease Control definitionEndometritisWithin 30 days of surgeryCenter for Disease Control definitionIdentification of pathogenic organism from tissue or fluidWithin 30 days of surgeryBased on Center for Disease Control definitionSurgical site infection (SSI): spaceWithin 30 days of surgery plus or for deep and/or organ/ spaceCenter for Disease Control definitionSepsisWithin 30 days of surgery for deep and/or organ/ spaceThird International Consensus Definitions for Sepsis and Sep SepsisPostoperative cancer outcomesCancer health-related quality of life Days alive and out of hospital Time to tumour progressionAt 90 days after surgery Time elapsed between treatme and tumour progression or death from any causeDisease-free survivalTime elapsed between treatme and death from any causeOverall survivalTime elapsed between treatme and death for any cause		Neurological infectious complication	Within 30 days of surgery	Center for Disease Control
Postoperative cancer outcomesCancer health-related quality of life cancer outcomesWithin 30 days of surgery Within 30 days of surgery Within 30 days of surgery Within 30 days of surgery minus within 90 days of surgery for deep and/or organ/space SSI in specific surgical subsets including breast, cardiac, spinal surgeryCenter for Disease Control definition Center for Disease Control definitionPostoperative cancer outcomesCancer health-related quality of life Days alive and out of hospital Time to tumour progressionWithin 30 days after surgery Within 30 days after surgery Time elapsed between treatme and tumour progression or death from specific cancer Overall survivalAt 90 days after surgery Time elapsed between treatme and tumour progression or death from specific cancer adeath from specific cancer			Within 30 days of surgery	
VisitiondefinitionIdentification of pathogenic organism from tissue or fluidWithin 30 days of surgeryBased on Center for Disease Control definitionSurgical site infection (SSI): superficial, deep, and/or organ/ spaceWithin 30 days of surgery plus or minus within 90 days of surgery plus or minus within 90 days of surgeryCenter for Disease Control definitionsSepsisWithin 30 days of surgeryThird International Consensus surgerySepsisWithin 30 days of surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life Days alive and out of hospital Time to tumour progressionAt 90 days after surgeryDisease-free survivalTime elapsed between treatme and tumour progression or death from any causeTime elapsed between treatme and dut our progression or death from specific cancer -specific survivalOverall survivalCurcer-specific survivalTime elapsed between treatme and death for any cause				definition
organism from tissue or fluid Surgical site infection (SSI): superficial, deep, and/or organ/ spaceWithin 30 days of surgery plus or minus within 90 days of surgery for deep and/or organ/space SSI in specific surgical subsets including breast, cardiac, spinal surgeryControl definition Center for Disease Control definitionsPostoperative cancer outcomesCancer health-related quality of life to tumour progressionWithin 30 days of surgery Within 30 days of surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life time to tumour progressionAt 90 days after surgery Time elapsed between treatme and tumour progression or death from any causeDisease-free survivalTime elapsed between treatme and tumour progression or death from any causeCancer-specific survivalTime elapsed between treatme and tumour progression or death from any causeCancer-specific survivalTime elapsed between treatme and tumour progression or death from any cause				definition
superficial, deep, and/or organ/ spaceminus within 90 days of surgery for deep and/or organ/space SSI in specific surgical subsets including breast, cardiac, spinal surgerydefinitionsSepsisWithin 30 days of surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life Days alive and out of hospital Time to tumour progressionAt 90 days after surgeryDisease-free survivalTime elapsed between treatme and tumour progression or death from any causeTime elapsed between treatme and death from specific canceOverall survivalOverall survivalTime elapsed between treatme and death of a cancem specific cancem		organism from tissue or fluid	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Control definition
SepsisWithin 30 days of surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of lifeThird International Consensus Definitions for Sepsis and Sep Shock (SEPSIS-3)Postoperative cancer outcomesCancer health-related quality of life'A cancer related quality of life instrument'Days alive and out of hospital Time to tumour progressionAt 90 days after surgery Time to tumour progression or death from tumour or cancer therapyDisease-free survivalTime elapsed between treatme and tumour progression or death from specific canceCancer-specific survivalTime elapsed between treatme and tumour progression or death from any causeCancer-specific survivalTime elapsed between treatme and death from specific canceOverall survivalTime elapsed between trial randomisation and death of a		superficial, deep, and/or organ/	minus within 90 days of surgery for deep and/or organ/space SSI in specific surgical subsets including breast, cardiac, spinal	
Septic shockWithin 30 days of surgeryThird International Consensus Definitions for Sepsis and Sep Shock (SEP5IS-3)Postoperative cancer outcomesCancer health-related quality of life'A cancer related quality of life instrument'Days alive and out of hospital Time to tumour progressionAt 90 days after surgeryTime elapsed between treatme and tumour progression or death from tumour or cancer therapyDisease-free survivalTime elapsed between treatme and tumour progression or death from tumour progression or death from any causeCancer-specific survivalTime elapsed between treatme and tumour progression or death from any causeOverall survivalTime elapsed between trial randomisation and death for and death of a		Sepsis		Definitions for Sepsis and Sept
Postoperative cancer outcomes Cancer health-related quality of life 'A cancer related quality of life instrument' Days alive and out of hospital Time to tumour progression At 90 days after surgery Time elapsed between treatme and tumour progression or death from tumour or cancer therapy Disease-free survival Time elapsed between treatme and tumour progression or death from any cause Cancer-specific survival Time elapsed between treatme and tumour progression or death from any cause Overall survival Time elapsed between treatme and death from specific cancer		Septic shock	Within 30 days of surgery	Third International Consensus Definitions for Sepsis and Septi
Time to tumour progression Time elapsed between treatme and tumour progression or death from tumour or cancer therapy Disease-free survival Time elapsed between treatme and tumour progression or death from any cause Cancer-specific survival Time elapsed between treatme and death from specific cancer Overall survival Time elapsed between trial randomisation and death of a	•	Cancer health-related quality of life		'A cancer related quality of life
therapyDisease-free survivalTime elapsed between treatme and tumour progression or death from any causeCancer-specific survivalTime elapsed between treatme and death from specific canceOverall survivalTime elapsed between trial randomisation and death of a		· ·	At 90 days after surgery	Time elapsed between treatmen and tumour progression or death from tumour or cancer
Cancer-specific survival Time elapsed between treatme and death from specific canc Overall survival Time elapsed between trial randomisation and death of a		Disease-free survival		therapy Time elapsed between treatmen and tumour progression or
Overall survival Time elapsed between trial randomisation and death of a		Cancer-specific survival		Time elapsed between treatmen
caube		Overall survival		

Table 1 Summary of published outcome measures advocated by the Standardised Endpoints in Perioperative Medicine (StEP) initiative.*Qualified recommendations or conditional endorsement.

384 | Hewson *et al.*

StEP domain	Sub-domains	Recommended time point(s) for assessments	Recommended assessment tool(s)/definition or other comments
Renal	Acute kidney injury		Kidney Disease: Improving Glob Outcomes (KDIGO) consensus criteria, including or excluding oliguric criteria
	Acute kidney disease	At 30 days after surgery	≥30% decline in estimated glomerular filtration rate from baseline in patients meeting th creatine-based KDIGO acute- kidney-injury criteria within 7 days of surgery
	Composite of death or renal replacement therapy	Preferably 30 or 90 days after surgery	, , ,
	Major adverse kidney events (MAKE) composite	e.g. 30 plus or minus 90 days after surgery	Mortality or renal replacement therapy of any duration or ≥30% decline in estimated glomerular filtration rate from baseline
Cardiovascular	Myocardial infarction		StEP expert panel consensus- derived definition
	Myocardial injury		Fourth Universal Definition of
	Cardiovascular death		Myocardial Infarction definition StEP expert panel consensus-
	Nonfatal cardiac arrest		derived definition StEP expert panel consensus-
	Coronary revascularisation	Within 30 days of surgery	derived definition StEP expert panel consensus-
	Major adverse cardiac events		derived definition StEP expert panel consensus-
	Pulmonary embolism		derived definition StEP expert panel consensus-
	Deep vein thrombosis		derived definition StEP expert panel consensus-
	Atrial fibrillation		derived definition New onset of irregularly irregul heart rate in the absence of P waves lasting at least 30 s or f
			the duration of the ECG
Pulmonary	Composite postoperative pulmonary complications		recording (if <30 s) StEP expert panel consensus- derived definition
	Pneumonia		Center for Disease Control
	Respiratory failure		definition Berlin definition of respiratory
	Re-institution of mechanical ventilation	Within 30 days of surgery or for more than 24 h after surgery	distress syndrome The need for tracheal re- intubation and mechanical ventilation after extubation. The inclusion of non-invasive ventilation may be considered
Mortality, morbidity, and	Mortality	Within 30 days and 1 yr of surgery	on a study-by-study basis.
organ failure	Morbidity		Clavien–Dindo classification*

The advent of fast-track general anaesthesia techniques, which emphasise avoidance of benzodiazepines and longeracting opioids, has challenged the previously held theory that spinal anaesthesia provides a superior recovery profile for ambulatory surgery patients. Perceived shortcomings of spinal anaesthesia include postoperative urinary retention, risk of transient neurologic symptoms (TNS), and delayed recovery of motor function, particularly with longer-acting local anaesthetics. The resurgence of chloroprocaine as an intrathecal anaesthetic agent has mitigated some of these concerns, because it is short-acting with a low incidence of urinary retention and TNS.²¹ A recent RCT comparing propofol-based general anaesthesia with spinal anaesthesia (40 mg chloroprocaine) with propofol-based sedation in patients undergoing outpatient knee arthroscopy demonstrated a faster time to discharge, longer time to first pain, and decreased cost with spinal anaesthesia.²² There was no difference between groups in terms of incidence of PONV, QoR-9 score, or patient

Table 2 Characteristics of included contemporary articles reporting neuraxial techniques and impact on standardised perioperative outcomes. CI, confidence interval; ERAS, enhanced recovery after surgery; HR, hazard ratio; IQR, inter-quartile range; NRS, numerical rating scale; OR, odds ratio; QoR-9; nine-point Quality of Recovery questionnaire; QoR-15; fifteen-point Quality of Recovery questionnaire; RD, risk difference; RR, relative risk; StEP, Standardised Endpoints in Perioperative Medicine. *Determined by institutional sponsorship for returned primary research or consensus guidelines, or institution of first or corresponding author for returned secondary research or opinion articles. [†]Tabulated comparisons only include those relevant to this review, individual articles may contain additional comparator groups which are not included in this table. [†]Tabulated perioperative outcomes only include those found in StEP domains, individual articles may contain additional non-StEP advocated outcomes of potential interest but are not included in this table. Outcomes include both primary and secondary (exploratory) outcomes reported in primary research.

First author, year, country of origin*	Design	Population	Comparison of relevance (intervention/control) [†]	Relevant StEP-advocated perioperative outcomes reported [‡]	Main conclusions relevant to StEP outcome domains
Koning, 2018, Netherlands	Single-centre randomised trial	Laparoscopic abdominal surgery	Spinal with intrathecal opioid/ Sham spinal with i.v. opioid	Pain intensity, patient satisfaction, time to mobilisation, nausea and vomiting	Spinal with intrathecal opioid associated with lower pain in the first 24 postoperative hours (median [IQR] 11-point NRS: 0.3 [0-3.8] vs 2.3 [1.3-4.3]; P=0.004.
Salicath, 2018, UK	Systematic review meta-analysis	Abdominal surgery	Epidural analgesia/i.v. patient-controlled analgesia	Pain intensity, nausea and vomiting, thromboembolism, death	Epidural analgesia reduces pain intensity at rest (moderate quality evidence, small effect) and on movement (low quality evidence, moderate effect). No differences detected in other outcomes.
O'Donnell, 2018, UK	Systematic review meta-analysis	Hip fracture	Spinal anaesthesia/general anaesthesia	Acute renal failure, pneumonia, myocardial infarction, death	There was no significant difference in 30-day mortality (OR 1.04 [95% CI 0.99–1.10]), pneumonia (OR 1.03 [95% CI 0.91 –1.17]), myocardial infarction (OR 0.96 [95% CI 0.87–1.05]) for spinal compared with general anaesthesia.
Gebhardt, 2018, Germany	Single-centre randomised trial	Knee arthroscopy	Spinal anaesthesia/general anaesthesia	Pain intensity, patient satisfaction, nausea and vomiting, quality of recovery	No significant group differences in overall postoperative satisfaction or quality of recovery on QoR-9.
Cummings, 2018, USA	Retrospective database analysis	Surgery for colorectal cancer	Epidural analgesia/non- epidural analgesia	Surgical site infection, sepsis, acute kidney injury, myocardial infarction, pneumonia, postoperative tracheal intubation, venous thromboembolism, prolonged mechanical ventilation, death	For open surgery: epidural analgesia was associated with fewer cardiorespiratory complications (OR 0.58 [95% CI 0.35–0.95]; P=0.03).
Kowark, 2018, Germany	Multicentre randomised trial	Age ≥65 yr with hip fracture	Spinal/general anaesthesia	Pain intensity, patient satisfaction, functional status, discharge disposition, death, non-fatal cardiac arrest, myocardial infarction, pneumonia, pulmonary embolism, unplanned postoperative tracheal intubation, prolonged mechanical ventilation	Published trial protocol: recruitment ongoing.
					Continue

Continued

First author, year, country of origin*	Design	Population	Comparison of relevance (intervention/control) [†]	Relevant StEP-advocated perioperative outcomes reported [‡]	Main conclusions relevant to StEP outcome domains
Brovman, 2019, USA	Retrospective database analysis	Ankle fracture fixation surgery	Neuraxial, and/or peripheral nerve block anaesthesia/ general anaesthesia	Surgical site infection, urinary tract infection, sepsis, myocardial infarction, acute kidney injury, pneumonia, unplanned postoperative tracheal intubation, prolonged mechanical ventilation, venous thromboembolism, death	No significant differences detected in any outcomes of neuraxial and/or peripheral nerve block anaesthesia and general anaesthesia.
Ban, 2019, USA	Narrative review	Colorectal surgery	Neuraxial analgesia/control	Pain intensity, nausea and vomiting, morbidity	For open surgery: compared with opioids, epidural analgesia provides superior postoperativ analgesia and decreases some cardiorespiratory morbidity.
Baar, 2019, Germany	Retrospective database analysis	Living donor nephrectomy	Epidural analgesia/non- epidural analgesia	Renal replacement therapy	Epidural analgesia associated with reduced delayed graft function.
Wink, 2019, Netherlands	Narrative review.	Adult perioperative practice	Epidural analgesia and anaesthesia	Myocardial infarction	'A potential influence of thoracic epidural anaesthesia on the incidence of perioperative myocardial infarction is favoured by some studies but remains to be clarified.'
Vester-Andersen, 2020, Denmark	Retrospective database analysis	Emergency abdominal surgery	Epidural analgesia/non- epidural analgesia	Death	Epidural analgesia associated with decreased risk of mortality in adjusted analysis at 30 days (OR 0.75 [95% CI 0.62–0.90]; P<0.01) and 90 days (OR 0.80 [95% CI 0.67–0.94]; P=0.01).
Malhas, 2019, Canada	Retrospective database analysis	Hip fracture	Spinal anaesthesia/general anaesthesia	Major adverse cardiac events, pulmonary embolism, death	Spinal anaesthesia associated with lower risk of pulmonary embolism (RR 0.36 [95% CI 0.12 -0.60]; P<0.001), and 90-day mortality (RR 0.74 [95% CI 0.52 -0.96]; P=0.037) but not major adverse cardiac events or deatl at 30 or 60 days.
Kaufmann, 2019, Germany	Retrospective database analysis	Oesophagectomy	Epidural analgesia/non- epidural analgesia	Postoperative pulmonary complications, unplanned postoperative tracheal intubation, death	Absence of epidural analgesia associated with postoperative pulmonary complications (OR 2.0 [95% CI 1.01–3.8]) and deatl (OR 3.9 [95% CI 1.6–9.7]).
Tang, 2020, Australia	Retrospective database analysis	Open liver resection	Spinal with intrathecal opioid/ multimodal analgesia alone	Pain intensity, nausea and vomiting, morbidity	Intrathecal opioid led to significantly reduced postoperative pain intensity in the first 24 postoperative hours (median [IQR] 11-point NRS 3 [-5] us 4 [3–6]; P=0.007).

First author, year, country of origin*	Design	Population	Comparison of relevance (intervention/control) [†]	Relevant StEP-advocated perioperative outcomes reported [‡]	Main conclusions relevant to StEP outcome domains
Desai, 2021, UK	Systematic review meta-analysis	Abdominal surgery	Epidural/transversus abdominis plane (TAP) block	Pain intensity, nausea and vomiting, surgical site infection, time to mobilisation, quality of recovery	Epidural analgesia statistically superior to TAP block in 12-h pain intensity at rest, but this difference is not clinically important.
Roberts, 2020, Canada	Retrospective database analysis	Lower limb revascularisation surgery	Neuraxial/general anaesthesia	Major adverse cardiac events, pneumonia, venous thromboembolism, acute kidney injury, death	Neuraxial anaesthesia associated with decreased mortality (adjusted OR 0.72 [95% CI 0.58 -0.89]; P<0.001) and major adverse cardiac events (adjusted OR 0.72 [95% CI 0.60 -0.87]; P<0.001).
.iu, 2020, China	Single-centre randomised trial	Age ≥65 yr undergoing laparoscopic colorectal surgery	Epidural with general anaesthesia/general anaesthesia alone	Pain intensity, nausea and vomiting, quality of recovery	Mean (standard deviation) QoR-15 at 24 h significantly higher following epidural analgesia (110.6 [4.4] vs 100.6 [6.5]; P<0.001).
ohnson, 2020, USA	Retrospective database analysis	Age ≥50 yr undergoing lower limb joint arthroplasty	Neuraxial anaesthesia/ general anaesthesia	Death	Among frailty-vulnerable patients, neuraxial anaesthesia was associated with improved survival (HR 0.49 [95% CI 0.27 -0.89]). No difference in risk between anaesthetic technique was observed in frail or non- frail cohorts.
Howle, 2022, Ireland	Systematic review network meta- analysis	Midline laparotomy	Neuraxial analgesia/ abdominal wall blocks/ wound infiltration/control	Pain intensity, nausea and vomiting, time to mobilisation	Low-quality evidence that epidural analgesia is associated with clinically superior pain scores compared with alternative continuous regional anaesthesia techniques for the first 24 postoperative hours
Kendall, 2021, USA	Retrospective database analysis	Primary total knee arthroplasty	Spinal/general anaesthesia	Surgical site infection, sepsis, renal failure, renal insufficiency, myocardial infarction, cardiac arrest, thromboembolic event, pneumonia, unplanned postoperative intubation, prolonged mechanical ventilation, death	General anaesthesia associated with higher incidence of minor adverse events (2.09% vs 0.51%; P<0.001) but not difference in serious adverse events (0.92% vs 0.66%; P=0.369) compared with spinal anaesthesia.
Dieu, 2021, Switzerland	Consensus recommendation	Open liver resection	Epidural analgesia/spinal intrathecal opioid/non- neuraxial analgesia	Pain intensity	Epidural analgesia, or bilateral subcostal TAP blocks, are recommended.
Du, 2021, China	Multicentre randomised trial	Age ≥60 yr undergoing major thoracic or abdominal surgery	Epidural analgesia/i.v. analgesia	Cancer-specific survival, recurrence-free survival, event-free survival, quality of life, overall survival	Epidural analgesia had no effect on overall, cancer-specific, recurrence-free, or event-free survival.

Continued

First author, year, country of origin*	Design	Population	Comparison of relevance (intervention/control) [†]	Relevant StEP-advocated perioperative outcomes reported [*]	Main conclusions relevant to StEP outcome domains
Wang, 2021, China	Systematic review meta-analysis	Primary total hip or knee arthroplasty	Spinal with intrathecal morphine/spinal without intrathecal morphine	Nausea and vomiting	No difference in incidence of nausea and vomiting (RR 1.21 [95% CI 0.98–1.49]; P=0.08).
Neuman, 2021, USA	Multicentre randomised trial	Age ≥50 yr with hip fracture	Spinal/general anaesthesia	Death, functional status, myocardial infarction, non- fatal cardiac arrest, pneumonia, pulmonary embolism, unplanned postoperative intubation, surgical site infection, acute kidney injury, urinary tract infection, time to mobilisation, discharge disposition	Spinal anaesthesia was not superior to general anaesthes with respect to survival and recovery of ambulation at 60 days (RR 1.03 [95% CI 0.84–1.27 P=0.83).
Li, 2022, China	Multicentre randomised trial.	Age ≥65 yr with hip fracture	Neuraxial with no sedation/ general anaesthesia	Death, nausea and vomiting, myocardial infarction, pneumonia, stroke	No difference in all-cause mortality at 30 days between neuraxial and general anaesthesia (RR 2.0 [95% CI 0.0. -6.5]).
Falk, 2021, Sweden	Multicentre randomised trial	Surgery for colorectal cancer	Epidural analgesia/patient- controlled i.v. opioid analgesia (PCA)	Disease-free survival, pain intensity, morbidity	Significantly lower pain intensit on activity with epidural vs PC on the first postoperative day. No significant difference between the epidural and PCA in disease-free survival (adjusted HR 1.19 [95% CI 0.61 -2.31]; P=0.61).
Xu, 2021, China	Multicentre randomised trial	Video-assisted thoracoscopic surgery for lung cancer	Epidural anaesthesia —analgesia/general anaesthesia alone	Recurrence-free survival, overall survival, cancer- specific survival	Epidural analgesia had no effect on overall, cancer-specific, recurrence-free survival compared with general anaesthesia alone.
Pirie, 2022, Australia	Narrative review	Major abdominal surgery	N/A	Pain intensity, quality of life, patient satisfaction, time to mobilisation, nausea and vomiting, morbidity, death	'Limited research exists on patient quality of recovery using specific analgesic techniques after intra- abdominal surgery. Poorly controlled postoperative pain afte major abdominal surgery should be a research priority'.
El-Boghdadly, 2022	Systematic review with qualitative synthesis	Colorectal surgery with ERAS protocol	Regional anaesthesia or analgesia/no, or placebo, regional anaesthesia or analgesia	Pain intensity, nausea and vomiting, time to mobilisation, quality of recovery, death	'Epidural analgesia had limited evidence of outcome benefits in open surgery, while spinal analgesia with intrathecal opioid may potentially be associated wi improved outcomes with no impa on length of stay in laparoscopic surgery, though dosing must be further investigated'.

Table 2 Continued							
First author, year, country of origin*	Design	Population	Comparison of relevance (intervention/control) [†]	Relevant StEP-advocated perioperative outcomes reported [‡]	Main conclusions relevant to StEP outcome domains		
Feray, 2022, Switzerland	Consensus recommendation	Video-assisted thoracoscopic surgery	Neuraxial analgesia/non- neuraxial analgesia	Pain intensity	Epidural analgesia not recommended for postoperative analgesia in video-assisted thoracoscopy		
Okuda, 2022, Japan	Single-centre randomised trial	Video-assisted thoracoscopic surgery	Epidural analgesia/general anaesthesia alone	Pain intensity, respiratory failure, pneumonia	No differences detected between groups in these secondary outcomes.		
Hasselager, 2022, Denmark	Retrospective database analysis	Surgery for colorectal cancer	Epidural analgesia/general anaesthesia	Cancer recurrence, death	No association between epidural analgesia and recurrence (HR 0.91 [95% CI 0.82–1.02]) or mortality (HR 1.01 [95% CI 0.92 –1.10]).		
Kunutsor, 2022, UK	Systematic review meta-analysis	Hip fracture	Spinal anaesthesia/general anaesthesia	Pain intensity, quality of life, acute kidney injury, pneumonia, acute coronary syndrome, death	Spinal anaesthesia reduced the risk of acute kidney injury (RR 0.59 [95% CI 0.39–0.89]). There were no significant differences in other outcomes.		
Lin, 2023, Australia	Retrospective database analysis	Hip fracture	Spinal anaesthesia/general anaesthesia	Death	Spinal anaesthesia not associated with altered risk of long-term death compared with general anaesthesia (adjusted HR 1.03 [95% CI 0.96-1.1]). Combined spinal and general anaesthesia associated with increased risk of long-term death (adjusted HI 1.12 [95% CI 1.02-1.24]).		

satisfaction. Another large, multicentre observational study in ambulatory patients undergoing mostly urological and orthopaedic surgery found that general anaesthesia demonstrated shorter times to urination and ambulation compared with spinal anaesthesia, although there was no difference in time to discharge.²³

Abdominal surgery

Quality of life measurement reporting in the literature is rare, as even recent studies continue to focus on the endpoints of pain, opioid consumption, and adverse events. Thoracic epidural analgesia (TEA) had previously been described as the gold standard for reducing postoperative pain and respiratory complications after major abdominal surgery.²⁴ Recently, a preference for minimally invasive surgical approaches has led to a decline in the use of epidural analgesia and a transition to intrathecal opioids and truncal nerve/plane blocks.²⁵ The use of spinal analgesia with intrathecal opioids is associated with improved pain outcomes compared with i.v. opioids alone in laparoscopic²⁶ and open²⁷ abdominal surgery, although opioid dosing remains an area of uncertainty.²⁸

There remains a role for TEA in open colorectal and hepatic surgeries. One review found that TEA was associated with superior pain control when compared with non-TEA analgesic protocols in open colorectal surgery.²⁹ Similarly, 2019 Enhanced Recovery After Surgery (ERAS®) Society Guidelines for Perioperative Care in Elective Colorectal Surgery recommend TEA as part of a multimodal analgesic protocol in open surgeries.³⁰ These recommendations are made despite the known higher incidence of major (permanent nerve injury) and minor (hypotension and urinary retention) adverse events with TEA compared with spinal or truncal nerve block.^{31–33}

TEA is not generally recommended in laparoscopic surgeries, especially when considering traditional outcomes such as pain, opioid consumption, and adverse events including hypotension and urinary retention.^{25,29,30} There may, however, be benefits to TEA in laparoscopic surgery for certain patient subgroups. Liu and colleagues³⁴ examined the effects of intraoperative TEA alongside general anaesthesia compared with general anaesthesia alone in the quality of recovery of older adults undergoing laparoscopic radical colonic resection for cancer. Patients with TEA had improved QoR-15 scores compared with general anaesthesia alone (110.60 vs 100.63, P<0.001 at 24 h; 116.43 vs 112.63, P=0.006 at 72 h).

Fascial plane blocks are popular components of modern multimodal analgesia after abdominal surgery. Since 2018, there have been several meta-analyses comparing the effect of transversus abdominis plane (TAP) blocks and TEA on outcomes after abdominal surgery. One SRMA examining 1220 patients in 18 RCTs, 13 of which involved open surgery, demonstrated a decrease in opioid consumption and pain scores at rest and on movement at 12 and 48 h in the TEA group, although these differences did not meet the prespecified threshold for clinical significance.³⁵ The quality of evidence contributing to the SRMA did not allow conclusions regarding other patient-centred outcomes such as PONV, recovery of intestinal function, or quality of recovery. Another SRMA, examining 568 patients undergoing mostly laparoscopic abdominal surgery in six RCTs, found no analgesic difference between TAP and TEA with the exception of improved pain with movement at 24 h, where TEA was deemed statistically, but not clinically, superior.³⁶ TAP block was determined to be superior to TEA with respect to opioid

consumption, time to ambulation, and duration of urinary catheterisation. This SRMA lends support to the use of TAP block over TEA for laparoscopic surgery. In contrast, for midline laparotomy, an SRMA and separate network meta-analysis including 36 trials with 2056 subjects indicated TEA to be superior to truncal facial plane block in pain scores and opioid consumption at 24 h.³⁷

There is a benefit using TEA in open hepatic surgery, with TEA demonstrating lower pain scores than alternate analgesic protocols, including wound catheters.²⁵ The Procedure-Specific Postoperative Pain Management (PROSPECT) working group examined 31 RCTs and three systemic reviews in order to develop recommendations for pain management after open liver resection, published in 2021.³⁸ The group determined that TEA provided better pain control in the first 24 h compared with subcostal TAP blocks and catheters, and also performed better than paravertebral blocks (PVBs). The PROSPECT recommendations for open hepatic surgery included paracetamol, NSAIDs, and either TEA or subcostal TAP blocks after surgery.

Thoracic surgery

Thoracic surgery is increasingly performed using less invasive, video-assisted thoracoscopic (VAT) techniques.^{39,40} The PROSPECT working group reviewed RCTs published during 2010–21 to develop guidelines for postoperative pain control in people undergoing VAT procedures, published in 2022.⁴¹ The group strongly recommended the inclusion of a regional analgesic technique to a standard multimodal protocol, with a preference for PVB over TEA. Although studies showed that TEA provided better or equivalent pain control to PVB, TEA is associated with a greater incidence of significant side-effects.⁴²

As with abdominal surgery, studies examining other patient-centred outcomes beyond pain control in thoracic surgery are few. One recent, albeit small, study examined health-related quality of life (HRQoL) in 65 patients undergoing thoracoscopic-laparoscopic oesophagectomy randomised to either intraoperative combined TEA and general anaesthesia or general anaesthesia alone.43 All patients then received postoperative pain relief with TEA. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life scores were assessed before surgery and at 7 and 30 days after surgery. The combined TEA-general group had better HRQoL scores, particularly in the social, emotional, and global health domains. Symptoms of sleep disorders, nausea, constipation, reflux, and cough difficulty were also less severe in the combined TEA-general group. Pain was also less severe in the combined group, although this finding was considered not to be clinically significant.

Infection and sepsis

Taken together with pulmonary and urinary tract infections (addressed elsewhere in this review), surgical site infections (SSIs) account for the majority of postoperative infections.⁴⁴ Given that SSIs complicate 0.5–3% of surgeries,⁴⁵ result in an average prolongation of hospital stay by 7–11 days,^{46,47} and a 78% readmission rate in patients discharged home,⁴⁸ testing of interventions to reduce SSI incidence, severity, or both has been a major research priority. Among known modifiable perioperative risk factors, prevention of sympathetic catecholamine-induced vasoconstriction and improved tissue

oxygenation have been offered as potential mechanisms by which neuraxial anaesthesia may positively impact on acute tissue healing and therefore SSI rates.^{49–53} The relative preservation of immune function arising from the decreased surgical stress response, reduced allogenic blood transfusion rates, and improved pain control with associated reduced sympathetic activation, all observed with neuraxial anaesthesia and analgesia, may also contribute to a reduced incidence of subsequent SSI.^{54–58}

The potentially catastrophic consequences of SSI after joint arthroplasty^{59,60} and the fact that lower limb surgery can be performed using either neuraxial or general anaesthetic means this surgical group has been intensively studied with regard to SSI and anaesthetic technique. In a landmark population study published in 2010, Chang and colleagues⁶¹ reported an adjusted odds ratio (aOR) of 2.21 (95% CI 1.25-3.90) for SSI under general anaesthesia vs neuraxial anaesthesia among 3081 patients who underwent arthroplasty surgery. Further retrospective analyses of registry data yielded conflicting results. One large observational study of 16 555 patients supported a positive impact of neuraxial anaesthesia on overall infection rate after joint arthroplasty; however, this effect was not observed for SSIs specifically.⁶² Similarly, analysis of 56 216 patients undergoing total knee arthroplasty at 45 hospitals reported no significant effect of anaesthetic type on rates of deep SSI.⁶³ In the absence of RCTs conducted on this topic, meta-analysis of published observational data is likely to provide the most compelling evidence, acknowledging the unavoidable methodological weaknesses of nonexperimentally derived data. Analysing a total of 362 029 patients undergoing lower limb arthroplasty, Zorrilla-Vaca and colleagues⁶⁴ reported neuraxial anaesthesia to be associated with a significant reduction in SSI compared with general anaesthesia (aOR 0.84, 95% CI 0.76-0.92). Addressing all forms of postoperative infection (rather than limited to SSI), further support for neuraxial techniques was reported by Memtsoudis and colleagues'65 analysis of 382 236 cases of arthroplasty, and, most recently, for all forms of regional anaesthesia by Wan and colleagues'44 analysis of 39 996 subjects prospectively gathered cases across multiple surgical specialties (OR 0.78, 95% CI 0.69-9.87). Of note, all these studies were reported before the most recent 5-year period. We were unable to identify more contemporary published evidence to further inform this topic.

In summary, whether neuraxial anaesthesia has an impact on SSI after surgery has been most extensively investigated after elective orthopaedic surgery. There is evidence that neuraxial anaesthesia reduces the risk of SSI compared with general anaesthesia; however, the certainty of this evidence is significantly weakened by underlying issues of internal validity arising from confounding and selection bias in observational research. In comparison with evidence supporting other infection-reducing modifications to the perioperative pathway, the likely contribution of neuraxial vs general anaesthetic technique to SSI is much less significant.

Postoperative cancer outcomes

The exploration of links between neuraxial (and, more generally, regional anaesthetic) techniques and cancer outcomes provides an instructive example of the challenges of bench-to-bedside research addressing specific health needs. Enthusiasm, born of encouraging immunological data and animal models of disease, supported by promising retrospective analyses, has been tempered by the more recent publication of experimental clinical trials demonstrating no link between regional anaesthesia and cancer outcomes in patients undergoing various forms of cancer resection surgery.

By reducing the neuroendocrine response to surgery, maintaining natural killer cell activity, and reducing the burden of circulating tumour cells, neuraxial anaesthesia offers plausible cellular benefit over general anaesthesia achieved with volatile agents and systemic opioids.^{66–72} Neuraxial anaesthesia may, therefore, offer a cancer benefit via an opioid-sparing effect, volatile-sparing effect, or both. In murine models of natural killer cell activity and cancer metastases under general anaesthesia, the addition of spinal anaesthesia significantly attenuated perioperative metastatic burden for breast⁷³ and liver⁷⁴ cancer. Identifying clinically important benefit from these cellular and animal findings has, however, proved elusive. Observational interrogation of procedural databases demonstrated possible increase in time to tumour recurrence and 3- and 5-year overall survival in patients with ovarian cancer,^{75,76} reduced risk of biochemical (i.e. prostate-specific antigen) recurrence and clinical cancer progression after radical prostatectomy,^{77,78} decreased all-cause mortality in patients with rectal cancer,⁷⁹ and improved recurrence and metastasis-free survival in patients after surgery for breast cancer.⁸⁰ Despite several retrospective and post hoc secondary analyses (and subsequent meta-analysis) showing no significant improvements in recurrence rates, disease-free survival, or overall survival with neuraxial anaesthesia,^{81–87} the question of whether fundamental choices in analgesic technique could affect time to tumour progression, disease-free survival, cancer-specific survival, or overall survival (all recommended core outcome measures, see Table 1) is clearly deserving of robust prospective experimental assessment.

Such assessment has been provided in several recently published studies. In a pre-planned, 5-year follow-up of 1712 older adults randomised to either combined epidural-general anaesthesia or general anaesthesia alone for major thoracoabdominal surgery, there was no difference in overall (adjusted hazard ratio [aHR] 1.07, 95% CI 0.92-1.24), cancerspecific (aHR 1.09, 95% CI 0.93-1.28), recurrence-free (aHR 0.97, 95% CI 0.84-1.12), or event-free survival (aHR 0.99, 95% CI 0.86–1.12).⁸⁸ Epidural analgesia did not, therefore, improve overall or cancer-specific long-term mortality in study participants, even though exposure to volatile and opioid medications was reduced in the epidural group. In a further RCT of 400 patients undergoing VAT surgery for lung cancer, combined epidural-general anaesthesia was no different to general anaesthesia in terms of recurrence-free (aHR 0.90, 95% CI 0.60-1.35), overall (aHR 1.12, 95% CI 0.64-1.96), or cancerspecific survival (aHR 1.08, 95% CI 0.61-1.91).⁸⁹ Although, in both trials, some patients underwent surgery for non-cancer disease (8% and 16%, respectively), the groups were balanced in this regard. In an RCT of 221 patients undergoing colorectal cancer surgery, disease-free survival was not improved by the provision of epidural analgesia in place of i.v. morphine (aHR 1.19, 95% CI 0.61–2.31).⁹⁰ Importantly, the above trials enrolled patients undergoing neurohumoral stress-provoking surgery and cannot be subject to the same analysis as trials assessing the impact of PVB in breast cancer surgery,^{91,92} namely that negative trial findings arose because the surgery itself elicits an insufficient host stress response.

In conclusion, in vitro and animal studies notwithstanding, recent observational and experimental human data indicate that neuraxial techniques have no significant effect on cancer recurrence or survival and that clinicians and patients should make decisions on whether to deploy neuraxial techniques based on other intended outcomes and patient preference.

Renal endpoints

The acute kidney injury (AKI) syndrome is described as a 'sentinel postoperative complication'⁹³ because, in addition to direct patient harm, it is an independent contributor to chronic kidney disease, concurrent extra-renal complications, prolonged critical care stay, length of hospital stay, increased healthcare costs, and death.^{94–101} Observed in 6.1–13.4% of patients undergoing major noncardiac surgery,^{97,102} AKI exists on a continuum with acute kidney disease and chronic kidney injury.^{103,104} In addition to AKI, StEP-advocated renal outcome measures are acute kidney disease, composite of death or renal replacement therapy, and a composite of major adverse kidney events (Table 1).

Most cases of postoperative AKI are acknowledged to have a multifactorial aetiology, with preoperative (e.g. diabetes mellitus, pre-existing kidney dysfunction), intraoperative (e.g. systemic and renal hypotension),^{105–107} and postoperative (e.g. nephrotoxin exposure) risk factors contributing to a common injury pathway of disrupted microcirculation, tissue inflammation, and parenchymal ischaemia.93 Given this multifactorial aetiology, it would appear unlikely that isolated single modifications to modern intraoperative anaesthetic technique (the choice of general vs neuraxial anaesthesia, for example) will, in itself, deliver significant improvement in the incidence or severity of postoperative renal outcomes.¹⁰⁸ Perhaps because of this, in contrast with outcomes related to patient comfort, comparatively few recent prospective studies of neuraxial vs general anaesthesia in noncardiac surgery address renal outcomes as their primary outcome.

Nevertheless, biologically plausible explanations can be offered to support possible effects of neuraxial anaesthesia on the kidney. The sympathetic nerve supply to the kidneys (T7-T11) decreases renal blood flow and increases tubular sodium resorption and renin secretion.¹⁰⁹ Given that the sympathetic nervous system is commonly disturbed by neuraxial techniques, some effect on acute renal physiology (if not long-term renal outcome) could reasonably be expected. Putative beneficial effects of neuraxial anaesthesia include altered microcirculation,¹¹⁰ reduced stress hormone response to surgery,¹¹¹ and improved postoperative coagulation.¹¹² The extent to which technique itself, rather than perioperative confounders such as concomitant fluid regimes and exposure to intraoperative hypotension, contribute to renal outcomes is unknown, and the direct comparative effects of neuraxial vs general anaesthesia are also uncertain. Although there is a no significant decrease in renal blood flow in healthy volunteers undergoing mid-thoracic neuraxial block,¹¹³ whether this is the case in patients at risk of adverse renal outcomes (e.g. patients with diabetes mellitus or chronic renal vascular disease) is not clear.

Turning to recent literature addressing outcomes, a retrospective population-data analysis of patients undergoing lower limb revascularisation surgery (and therefore at substantial risk of AKI) demonstrated that patients undergoing neuraxial anaesthesia had an unadjusted OR of AKI of 0.48 (95% CI 0.34–0.67) compared with patients receiving general anaesthesia.¹¹⁴ Owing to lack of statistical power, the authors could only perform regression adjustment for confounders on a composite outcome combining cardiac, renal, and pulmonary complications, so the extent of any true effect on renal outcome by anaesthetic technique remains uncertain. Similarly, in patients undergoing lower limb arthroplasty, metaanalysis has demonstrated that neuraxial anaesthesia is protective against acute postoperative renal failure, especially when administered as a sole technique, rather than in addition to general anaesthesia (OR 0.69, 95% CI 0.59–0.81, P<0.0001 for total hip arthroplasty; OR 0.73, 95% CI 0.65–0.82, P<0.0001 for total knee arthroplasty).¹⁴ In the special circumstance of living kidney donation, the addition of epidural analgesia to general anaesthesia has been retrospectively linked with a lower rate of delayed graft function,¹¹⁰ but further prospective data are needed to validate this hypothesis-generating, retrospective study.

Cardiovascular outcomes

The readily observable acute alterations in cardiovascular status, including heart rate, arterial blood pressure, and vasomotor tone induced by neuraxial techniques,^{115,116} and experimental evidence that TEA improves coronary function and myocardial oxygen balance in ischaemic heart disease^{117–121} has led researchers to continue to examine whether neuraxial analgesia could positively impact perioperative endpoints of myocardial health in surgical populations. There is conflicting post hoc observational $^{122}\ {\rm and}\$ experimental^{123,124} evidence regarding the association between neuraxial anaesthesia (either as a sole technique or in combination with general anaesthesia) and myocardial infarction or various composite outcomes encompassing cardiovascular or cardiopulmonary morbidity after noncardiac surgery. In the decade preceding our literature search, two highly cited meta-analyses showed that TEA did not demonstrate a reduced risk of myocardial infarction.^{125,126} Pöpping and colleagues¹²⁵ analysed data from 9044 patients in 125 trials encompassing all types of surgery up to 2012. They identified a non-statistically significant effect of epidural analgesia in reducing the rate of myocardial infarction compared with non-epidural regimes (OR 0.73, 95% CI 0.50-1.06), but did detect significantly reduced rates of atrial fibrillation (OR 0.63, 95% CI 0.49-0.82) and supraventricular tachycardia (OR 0.69, 95% CI 0.55-0.87). Similarly, a 2014 meta-analysis of data from 849 subjects undergoing any form of open or laparoscopic surgery reported no difference in risk of myocardial infarction between neuraxial and general anaesthetic techniques (RR 1.17, 95% CI 0.57-2.37) or between combined neuraxial-general anaesthesia vs general anaesthesia alone (RR 0.69, 95% CI 0.44-1.09). This contrasts with a metaanalysis of 1498 patients undergoing exclusively open aortic surgery which showed that adding an epidural to general anaesthesia reduced the rate of myocardial infarction (RR 0.54, 95% CI 0.30-0.97; number needed to treat [NNT] for one additional beneficial outcome 28).¹²⁷ The differential effect of epidural analgesia on cardiac outcome appears to depend on the degree of systemic surgical insult. The physiological challenge of open thoracoabdominal surgery may offer neuraxial block the opportunity to prevent cardiovascular harm that laparoscopic surgeries do not. This was demonstrated in a retrospective, propensity-matched analysis of patients undergoing colorectal surgery using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) data.¹²⁸ Although the 1611 patients who underwent open colectomy with TEA experienced fewer cardiopulmonary

complications than matched patients without epidural (OR 0.58, 95% CI 0.35–0.95), this effect was not observed when both open and laparoscopic surgeries were analysed (OR 0.87, 95% CI 0.68–1.11).

In conclusion, current evidence indicates that TEA exerts a beneficial effect on cardiovascular outcomes in specific pathologies such as medically resistant angina pectoralis and for surgical populations undergoing major open procedures in terms of myocardial infarction. Translating population-level data on cardiovascular benefit to inform the care of individual patients undergoing specific surgery is challenging. Potential protection from perioperative ischaemic heart disease may be offset by the neuraxial sympathectomy causing greater perioperative haemodynamic instability, especially in high-risk patients,¹¹⁶ with higher rates of perioperative hypotension being a consistent finding in clinical trials.¹²⁹

Pulmonary complications

Reducing the risk of postoperative pneumonia, respiratory failure, and mechanical ventilation continues to be one of the major justifications offered by clinicians for TEA in major thoracoabdominal surgery, even though the baseline risk of such events has decreased markedly over the past 40 years, probably owing to advances in surgical technique, perioperative monitoring, on-demand analgesia systems, and protocolisation of enhanced recovery after surgery.¹³⁰ The association between effective analgesia and the ability to engage in postoperative respiratory therapy after major thoracoabdominal surgery is readily observable in clinical practice, and the natural history and pathophysiology of postoperative pulmonary complications is well described.¹³¹ Even so, it is striking that even in high-risk surgeries such as oesophagectomy via thoracotomy, the evidence that TEA reduces the incidence of pulmonary complications is inconsistent.^{132–137} Across all forms of surgery, the risk of respiratory depression (OR 0.61, 95% CI 0.39-0.93), atelectasis (OR 0.67, 95% CI 0.48-0.93), and pneumonia (OR 0.56, 95% CI 0.45-0.70) is reduced by epidural analgesia. An RR reduction of 25% in total composite postoperative pulmonary outcomes was reported by Odor and colleagues¹³⁸ in their 2020 meta-analysis of data derived from all noncardiac surgeries. A 2016 meta-analysis demonstrating a reduced rate of postoperative respiratory failure in patients undergoing open abdominal aortic aneurysm repair (OR 0.69, 95% CI 0.56-0.85) informed the 2022 ERAS Society and Society for Vascular Surgery consensus statement on open aortic perioperative care that 'Mid-thoracic (T6-T9) epidural analgesia is recommended intraoperatively'.¹³

Importantly, the observed beneficial effect of TEA on pneumonia appears to have decreased over time, with one analysis showing a historical NNT of 4 using data from the 1970s but NNT of 25 using trial data to 2015 when TEA is compared with non-TEA control analgesia. The historical bias favouring epidural and other neuraxial techniques in comparison with non-neuraxial analgesia was acknowledged in multidisciplinary pain guidance endorsed by the American Pain Society, American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, which nevertheless stated clinicians should 'routinely consider use of epidural or spinal analgesia for management of postoperative pain in patients who undergo major thoracic and abdominal procedures, cesarean section, and hip and lower extremity surgeries, particularly in patients at risk for cardiac complications, pulmonary complications, or prolonged ileus'. $^{\rm 140}$

Mortality

In the 5-year period covered by this literature search, we identified highly cited studies evaluating the impact of neuraxial techniques on mortality after emergency abdominal,¹⁴¹ elective arthroplasty,¹⁴ and hip fracture surgery.¹⁸ In their 2020 population-based cohort study enrolling 4920 adults undergoing emergency abdominal surgery, Vester-Andersen and colleagues¹⁴¹ reported an adjusted association between TEA and reduced 30-day (OR 0.75, 95% CI 0.62-0.90) and 90-day (OR 0.80, 95% CI 0.67–0.94) mortality. The authors theorise that the mortality benefit was observed because epidural analgesia reduces postoperative ileus and improves postoperative pain, mobilisation, deep breathing, and coughing, thereby reducing pulmonary complications and mortality. These effects may be most frequently observed in patients undergoing emergency laparotomy. This mortality benefit is consistent with previous population-based evidence¹⁴² and a meta-analysis of TEA in all forms of surgery conducted under general anaesthesia which showed a mortality rate of 2.0% among recipients of TEA vs 3.2% with non-TEA opioid-based analgesia (OR 0.69, 95% CI 0.51-0.92; NNT 90, 95% CI 55-244).125

In the setting of lower limb orthopaedic surgery, a 2019 meta-analysis of randomised and observation evidence by the International Consensus on Anaesthesia-Related Outcomes after Surgery (ICAROS) group demonstrated that neuraxial anaesthesia offered superior mortality compared with general anaesthesia for patients undergoing primary hip (OR 0.67, 95% CI 0.57–0.80) but not knee (OR 0.83 95% CI 0.60–1.15) arthroplasty.¹⁴ There is some evidence that the observed mortality benefit of neuraxial anaesthesia in arthroplasty may be particularly pertinent to patients vulnerable to frailty.¹⁴³

In keeping with previously published retrospective data showing no difference between neuraxial and general anaesthesia on survival after hip fracture surgery,^{144–146} neither the REGAIN¹⁸ nor Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery (RAGA)¹⁹ trials found neuraxial anaesthesia to be superior to general anaesthesia in 60- or 30day mortality, respectively. Meta-analysis of data from these and other trials, published in 2022, reported no difference in mortality up to 120 days between anaesthetic techniques,¹⁴⁷ a finding in keeping with previous meta-analysis of both randomised and observational evidence showing no mortality benefit with neuraxial anaesthesia in hip fracture surgery.¹⁴⁸

Conclusions

In this review, we have synthesised pivotal research on neuraxial techniques published in the preceding 5 years relevant to the StEP initiative domains in patient comfort, infection, cancer, renal, cardiovascular, pulmonary, and mortality outcomes. In addition to these contemporary studies, we have explored returned citation lists to highlight the foundational scholarship upon which ongoing research into the relationship between patient outcome and epidural or spinal anaesthesia is based. It should be noted that several of the cited publications were published before the StEP initiative, and consequently, the fit of reported outcomes to those presented in this manuscript is imperfect. Nevertheless, we consider the use of the StEP framework to be important and useful. A consistent finding of this review, notable across all StEP domains, is that biological plausibility, mechanistic support, and observational association between neuraxial techniques and clinical outcomes is frequently reported in the literature, but convincing experimental evidence of causation between independent (anaesthetic technique) and dependent (patient outcome) variables in large clinical trials or meta-analysis is much less frequently observed. It is noteworthy that of the 34 articles returned by our search of the most recent 5 years of literature, 24 are secondary analyses and only 10 are clinical studies reporting new primary data.

This review has several limitations. We have not included environmental sustainability, cognition, or equality of access to treatment as outcome domains of interest because these do not feature as current StEP domains; however, we acknowledge that these are of increasing professional concern and are likely to feature heavily in future studies examining neuraxial techniques. Our intention in performing this review was to provide a narrative description of key recent outputs on this topic, based on a structured search of the published literature and encompassing multiple research methodologies including basic science, observational, and experimental designs. This scope, together with the intention to organise the review according to the full range of StEP-advocated domains, means that new quantitative secondary analyses or formal quality assessment of all included studies was not undertaken.

In undertaking this review, we chose to limit our search strategy to the previous 5 years. Although a time-limited search scope might be considered a weakness in evidence synthesis exercises, we chose to focus on recent evidence in view of the rapid evolution of surgical techniques and perioperative treatments. This limited search window also allowed a more detailed evaluation of the evidence. To complement our work on neuraxial techniques, we note the recent publication of Admiraal and colleagues,¹⁴⁹ where outcomes after the use of peripheral regional anaesthesia are considered from the most recent 10-yr period. This work is complementary to that presented here, and we commend it to the reader.

We have not considered cardiac, obstetric, and paediatric surgery separately. Although neuraxial techniques have specific indications and demonstrated benefits in these subgroups, we chose to limit the scope of this work in order to consider the impact of regional anaesthesia on outcomes in the broader population. We acknowledge that a similar exercise is required in special populations. We also acknowledge our search strategy may have failed to identify some relevant scholarly outputs on this topic or that we omitted published works from narrative description because we judged them less impactful than the cited studies. This subjective element of study selection is a recognised weakness of any narrative synthesis. Finally, we have not considered technical complications and direct adverse events arising from neuraxial techniques, although our literature search returned recently published examinations of this important topic.¹⁵⁰

To conclude, we have summarised extensive research published in the last 5 years into the possible impact of neuraxial techniques on patient outcomes. Evidence of positive impact is best established for domains of patient comfort, pulmonary complications, and mortality—particularly in the setting of major open thoracoabdominal surgery. In contrast, recent evidence does not strongly support a significant impact of neuraxial techniques on cancer, renal, infective, or cardiovascular outcomes after noncardiac surgery in most patient groups. Future clinical trials and subsequent metaanalyses on neuraxial techniques will benefit from more structured inclusion of StEP-advocated patient outcomes.

Authors' contributions

Review design and planning: DWH, JGH Review conduct, writing and revision of manuscript: all authors

Declarations of interest

DWH and JGH accept fees for advising in civil, criminal, and coronial medicolegal matters. DWH and TT are members of the associate editorial board of the British Journal of Anaesthesia. JGH is associate editor-in-chief of the British Journal of Anaesthesia.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bja.2024.04.044.

References

- Gropper MA, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Leslie K, eds. Miller's Anesthesia, 9th edn. Elsevier, Philadelphia, PA, USA
- Cook TM, Counsell D, Wildsmith JAW. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009; 102: 179–90
- Boney O, Moonesinghe SR, Myles PS, Grocott MPW, StEP-COMPAC group. Core Outcome Measures for Perioperative and Anaesthetic Care (COMPAC): a modified Delphi process to develop a core outcome set for trials in perioperative care and anaesthesia. Br J Anaesth 2022; 128: 174–85
- Møller MH. Patient-important outcomes and core outcome sets: increased attention needed. Br J Anaesth 2019; 122: 408–10
- Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc 2018; 106: 531–4
- Myles PS, Boney O, Botti M, et al. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: patient comfort. Br J Anaesth 2018; 120: 705–11
- Moonesinghe SR, Jackson AIR, Boney O, et al. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine initiative: patientcentred outcomes. Br J Anaesth 2019; 123: 664–70
- Barnes J, Hunter J, Harris S, et al. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: infection and sepsis. Br J Anaesth 2019; 122: 500–8
- Buggy DJ, Freeman J, Johnson MZ, et al. Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomes. Br J Anaesth 2018; 121: 38–44
- 10. McIlroy DR, Bellomo R, Billings 4th FT, et al. Systematic review and consensus definitions for the Standardised

Endpoints in Perioperative Medicine (StEP) initiative: renal endpoints. Br J Anaesth 2018; **121**: 1013–24

- **11.** Beattie WS, Lalu M, Bocock M, et al. Systematic review and consensus definitions for the Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes. *Br J Anaesth* 2021; **126**: 56–66
- **12.** Abbott TEF, Fowler AJ, Pelosi P, et al. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. *Br J Anaesth* 2018; **120**: 1066–79
- 13. Jackson AIR, Boney O, Pearse RM, et al. Systematic reviews and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: mortality, morbidity, and organ failure. Br J Anaesth 2023; 130: 404–11
- **14.** Memtsoudis SG, Cozowicz C, Bekeris J, et al. Anaesthetic care of patients undergoing primary hip and knee arthroplasty: consensus recommendations from the International Consensus on Anaesthesia-Related Outcomes after Surgery group (ICAROS) based on a systematic review and meta-analysis. Br J Anaesth 2019; **123**: 269–87
- **15.** Kendall MC, Cohen AD, Principe-Marrero S, Sidhom P, Apruzzese P, De Oliveira G. Spinal versus general anesthesia for patients undergoing outpatient total knee arthroplasty: a national propensity matched analysis of early postoperative outcomes. BMC Anesthesiol 2021; **21**: 226
- 16. Gonvers E, El-Boghdadly K, Grape S, Albrecht E. Efficacy and safety of intrathecal morphine for analgesia after lower joint arthroplasty: a systematic review and metaanalysis with meta-regression and trial sequential analysis. Anaesthesia 2021; 76: 1648–58
- 17. Wang LM, Zhang Z, Yao RZ, Wang GL. The role of intrathecal morphine for postoperative analgesia in primary total joint arthroplasty under spinal anesthesia: a systematic review and meta-analysis. Pain Med 2021; 22: 1473–84
- Neuman MD, Feng R, Carson JL, et al. Spinal anesthesia or general anesthesia for hip surgery in older adults. N Engl J Med 2021; 385: 2025–35
- **19.** Li T, Li J, Yuan L, et al. Effect of regional vs general anesthesia on incidence of postoperative delirium in older patients undergoing hip fracture surgery: the RAGA randomized trial. JAMA 2022; **327**: 50–8
- 20. Kowark A, Adam C, Ahrens J, et al. Improve hip fracture outcome in the elderly patient (iHOPE): a study protocol for a pragmatic, multicentre randomised controlled trial to test the efficacy of spinal versus general anaesthesia. BMJ Open 2018; 8, e023609
- Stewart J, Gasanova I, Joshi GP. Spinal anesthesia for ambulatory surgery: current controversies and concerns. *Curr Opin Anaesthesiol* 2020; 33: 746–52
- 22. Gebhardt V, Zawierucha V, Schöffski O, Schwarz A, Weiss C, Schmittner MD. Spinal anaesthesia with chloroprocaine 1% versus total intravenous anaesthesia for outpatient knee arthroscopy: a randomised controlled trial. *Eur J Anaesthesiol* 2018; **35**: 774–81
- Capdevila X, Aveline C, Delaunay L, et al. Factors determining the choice of spinal versus general anesthesia in patients undergoing ambulatory surgery: results of a multicenter observational study. Adv Ther 2020; 37: 527–40
- 24. Rigg JRA, Jamrozik K, Myles PS, et al. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. *Lancet* 2002; **359**: 1276–82

- **25.** Pirie K, Traer E, Finniss D, Myles PS, Riedel B. Current approaches to acute postoperative pain management after major abdominal surgery: a narrative review and future directions. Br J Anaesth 2022; **129**: 378–93
- **26.** Koning MV, Teunissen AJW, van der Harst E, Ruijgrok EJ, Stolker RJ. Intrathecal morphine for laparoscopic segmental colonic resection as part of an enhanced recovery protocol: a randomized controlled trial. *Reg Anesth Pain Med* 2018; **43**: 166–73
- **27.** Tang J, Churilov L, Tan CO, et al. Intrathecal morphine is associated with reduction in postoperative opioid requirements and improvement in postoperative analgesia in patients undergoing open liver resection. *BMC Anesthesiol* 2020; **20**: 207
- El-Boghdadly K, Jack JM, Heaney A, et al. Role of regional anesthesia and analgesia in enhanced recovery after colorectal surgery: a systematic review of randomized controlled trials. *Reg Anesth Pain Med* 2022; 47: 282–92
- **29.** Ban KA, Gibbons MM, Ko CY, et al. Evidence review conducted for the agency for healthcare research and quality safety program for improving surgical care and recovery: focus on anesthesiology for colorectal surgery. *Anesth Analg* 2019; **128**: 879–89
- 30. Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. World J Surg 2019; 43: 659–95
- 31. Salicath JH, Yeoh EC, Bennett MH. Epidural analgesia versus patient-controlled intravenous analgesia for pain following intra-abdominal surgery in adults. Cochrane Database Syst Rev 2018; 8: CD010434
- Hewson DW, Bedforth NM, Hardman JG. Peripheral nerve injury arising in anaesthesia practice. Anaesthesia 2018; 73: 51–60
- Hewson DW, Bedforth NM, Hardman JG. Spinal cord injury arising in anaesthesia practice. Anaesthesia 2018; 73: 43–50
- **34.** Liu Q, Lin JY, Zhang YF, et al. Effects of epidural combined with general anesthesia versus general anesthesia on quality of recovery of elderly patients undergoing laparoscopic radical resection of colorectal cancer: a prospective randomized trial. *J Clin Anesth* 2020; **62**, 109742
- **35.** Desai N, El-Boghdadly K, Albrecht E. Epidural vs. transversus abdominis plane block for abdominal surgery a systematic review, meta-analysis and trial sequential analysis. *Anaesthesia* 2021; **76**: 101–17
- 36. Hamid HKS, Marc-Hernández A, Saber AA. Transversus abdominis plane block versus thoracic epidural analgesia in colorectal surgery: a systematic review and meta-analysis. Langenbecks Arch Surg 2021; 406: 273–82
- 37. Howle R, Ng S-C, Wong H-Y, Onwochei D, Desai N. Comparison of analgesic modalities for patients undergoing midline laparotomy: a systematic review and network meta-analysis. Can J Anaesth 2022; 69: 140–76
- 38. Dieu A, Huynen P, Lavand'homme P, et al. Pain management after open liver resection: Procedure-Specific Postoperative Pain Management (PROSPECT) recommendations. Reg Anesth Pain Med 2021; 46: 433–45
- **39.** Detterbeck F, Molins L. Video-assisted thoracic surgery and open chest surgery in lung cancer treatment: present and future. *J Vis Surg* 2016; **2**: 173
- **40.** Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery versus open lobectomy for

primary non-small-cell lung cancer: a propensitymatched analysis of outcome from the European Society of Thoracic Surgeon database. *Eur J Cardiothorac Surg* 2016; **49**: 602–9

- 41. Feray S, Lubach J, Joshi GP, Bonnet F, Van de Velde M, PROSPECT Working Group of the European Society of Regional Anaesthesia and Pain Therapy. PROSPECT guidelines for video-assisted thoracoscopic surgery: a systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia 2022; 77: 311–25
- **42.** Yeung JHY, Gates S, Naidu BV, Wilson MJA, Gao Smith F. Paravertebral block versus thoracic epidural for patients undergoing thoracotomy. *Cochrane Database Syst Rev* 2016; **2**: CD009121
- 43. Han X, Lu Y, Fang Q, Fang P, Wong GTC, Liu X. Effects of epidural anesthesia on quality of life in elderly patients undergoing esophagectomy. Semin Thorac Cardiovasc Surg 2021; 33: 276–85
- **44.** Wan YI, Patel A, Abbott TEF, et al. Prospective observational study of postoperative infection and outcomes after noncardiac surgery: analysis of prospective data from the VISION cohort. Br J Anaesth 2020; **125**: 87–97
- Seidelman JL, Mantyh CR, Anderson DJ. Surgical site infection prevention: a review. JAMA 2023; 329: 244–52
- **46.** Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PloS One 2009; **4**, e8305
- 47. Zimlichman E, Henderson D, Tamir O, et al. Health careassociated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013; 173: 2039–46
- Ming DY, Chen LF, Miller BA, Sexton DJ, Anderson DJ. The impact of depth of infection and postdischarge surveillance on rate of surgical-site infections in a network of community hospitals. Infect Control Hosp Epidemiol 2012; 33: 276–82
- **49.** Jonsson K, Jensen JA, Goodson 3rd WH, et al. Tissue oxygenation, anemia, and perfusion in relation to wound healing in surgical patients. *Ann Surg* 1991; **214**: 605–13
- Hopf HW, Hunt TK, West JM, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg 1997; 132: 997–1004. ; discussion 1005
- 51. Buggy DJ, Doherty WL, Hart EM, Pallett EJ. Postoperative wound oxygen tension with epidural or intravenous analgesia: a prospective, randomized, single-blind clinical trial. Anesthesiology 2002; 97: 952–8
- 52. Kabon B, Fleischmann E, Treschan T, Taguchi A, Kapral S, Kurz A. Thoracic epidural anesthesia increases tissue oxygenation during major abdominal surgery. Anesth Analg 2003; 97: 1812–7
- 53. Treschan TA, Taguchi A, Ali SZ, et al. The effects of epidural and general anesthesia on tissue oxygenation. Anesth Analg 2003; 96: 1553–7
- 54. Tønnesen E, Wahlgreen C. Influence of extradural and general anaesthesia on natural killer cell activity and lymphocyte subpopulations in patients undergoing hysterectomy. Br J Anaesth 1988; 60: 500–7
- McBride WT, Armstrong MA, McBride SJ. Immunomodulation: an important concept in modern anaesthesia. Anaesthesia 1996; 51: 465–73
- **56.** Carli F, Halliday D. Continuous epidural blockade arrests the postoperative decrease in muscle protein fractional

synthetic rate in surgical patients. Anesthesiology 1997; 86: 1033-40

- Ciepichał J, Kübler A. Effect of general and regional anesthesia on some neutrophil functions. Arch Immunol Ther Exp 1998; 46: 183–92
- Guay J. The effect of neuraxial blocks on surgical blood loss and blood transfusion requirements: a meta-analysis. J Clin Anesth 2006; 18: 124–8
- 59. Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am 2009; 91: 128–33
- Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27: 1247–54
- Chang CC, Lin HC, Lin HW, Lin HC. Anesthetic management and surgical site infections in total hip or knee replacement: a population-based study. *Anesthesiology* 2010; 113: 279–84
- **62.** Liu J, Ma C, Elkassabany N, Fleisher LA, Neuman MD. Neuraxial anesthesia decreases post-operative systemic infection risk compared to general anesthesia in knee arthroplasty. *Anesth Analg* 2013; **117**: 1010–6
- **63.** Namba RS, Inacio MCS, Paxton EW. Risk factors associated with deep surgical site infections after primary total knee arthroplasty: an analysis of 56,216 knees. *J Bone Joint Surg Am* 2013; **95**: 775–82
- **64.** Zorrilla-Vaca A, Grant MC, Mathur V, Li J, Wu CL. The impact of neuraxial versus general anesthesia on the incidence of postoperative surgical site infections following knee or hip arthroplasty: a meta-analysis. *Reg Anesth Pain Med* 2016; **41**: 555–63
- **65.** Memtsoudis SG, Sun X, Chiu YL, et al. Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. *Anesthesiology* 2013; **118**: 1046–58
- Peterson PK, Molitor TW, Chao CC. Mechanisms of morphine-induced immunomodulation. Biochem Pharmacol 1993; 46: 343–8
- 67. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121: 834–40
- **68**. Eisenstein TK, Hilburger ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 1998; **83**: 36–44
- **69**. Brand JM, Kirchner H, Poppe C, Schmucker P. The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. *Clin Immunol Immunopathol* 1997; **83**: 190–4
- 70. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82: 492
- 71. Wodehouse T, Demopoulos M, Petty R, et al. A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery. Pain 2019; 160: 2691–8
- 72. Okuda J, Suzuki T, Wakaizumi K, Kato J, Yamada T, Morisaki H. Effects of thoracic epidural anesthesia on systemic and local inflammatory responses in patients undergoing lung cancer surgery: a randomized controlled trial. J Cardiothorac Vasc Anesth 2022; 36: 1380–6
- 73. Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, Ben-Eliyahu S. Attenuation of the tumor-promoting

effect of surgery by spinal blockade in rats. Anesthesiology 2001; **94**: 1066–73

- 74. Wada H, Seki S, Takahashi T, et al. Combined spinal and general anesthesia attenuates liver metastasis by preserving Th1/Th2 cytokine balance. Anesthesiology 2007; 106: 499–506
- **75.** de Oliveira GS, Ahmad S, Schink JC, Singh DK, Fitzgerald PC, McCarthy RJ. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. *Reg Anesth Pain Med* 2011; **36**: 271–7
- 76. Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth 2011; 106: 814–22
- 77. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; **109**: 180–7
- 78. Wuethrich PY, Hsu Schmitz SF, Kessler TM, et al. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study. *Anesthesiology* 2010; 113: 570–6
- **79.** Gupta A, Björnsson A, Fredriksson M, Hallböök O, Eintrei C. Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in Central Sweden. *Br J Anaesth* 2011; **107**: 164–70
- **80.** Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? *Anesthesiology* 2006; **105**: 660–4
- Cakmakkaya OS, Kolodzie K, Apfel CC, Pace NL. Anaesthetic techniques for risk of malignant tumour recurrence. Cochrane Database Syst Rev 2014; 2014, CD008877
- **82.** Forget P, Tombal B, Scholtès JL, et al. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? *Eur J Anaesthesiol* 2011; **28**: 830–5
- **83.** Gottschalk A, Ford JG, Regelin CC, et al. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. *Anesthesiology* 2010; **113**: 27–34
- 84. Day A, Smith R, Jourdan I, Fawcett W, Scott M, Rockall T. Retrospective analysis of the effect of postoperative analgesia on survival in patients after laparoscopic resection of colorectal cancer. Br J Anaesth 2012; 109: 185–90
- 85. Hasselager RP, Hallas J, Gögenur I. Epidural analgesia and recurrence after colorectal cancer surgery: a Danish retrospective registry-based cohort study. Anesthesiology 2022; 136: 459–71
- 86. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JRA, Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 2011; 342: d1491
- **87.** Tsui BCH, Rashiq S, Schopflocher D, et al. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. *Can J Anaesth* 2010; **57**: 107–12
- 88. Du YT, Li YW, Zhao BJ, et al. Long-term survival after combined epidural-general anesthesia or general

anesthesia alone: follow-up of a randomized trial. Anesthesiology 2021; **135**: 233–45

- 89. Xu ZZ, Li HJ, Li MH, et al. Epidural anesthesia-analgesia and recurrence-free survival after lung cancer surgery: a randomized trial. Anesthesiology 2021; 135: 419–32
- 90. Falk W, Magnuson A, Eintrei C, et al. Comparison between epidural and intravenous analgesia effects on disease-free survival after colorectal cancer surgery: a randomised multicentre controlled trial. Br J Anaesth 2021; 127: 65–74
- **91.** Karmakar MK, Samy W, Lee A, et al. Survival analysis of patients with breast cancer undergoing a modified radical mastectomy with or without a thoracic paravertebral block: a 5-year follow-up of a randomized controlled trial. *Anticancer Res* 2017; **37**: 5813–20
- **92.** Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. *Lancet* 2019; **394**: 1807–15
- 93. Prowle JR, Forni LG, Bell M, et al. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative. Nat Rev Nephrol 2021; 17: 605–18
- 94. Pearse RM, Moreno RP, Bauer P, et al. Mortality after surgery in Europe: a 7 day cohort study. Lancet 2012; 380: 1059–65
- **95.** Gameiro J, Fonseca JA, Neves M, Jorge S, Lopes JA. Acute kidney injury in major abdominal surgery: incidence, risk factors, pathogenesis and outcomes. *Ann Intensive Care* 2018; **8**: 22
- **96.** Meersch M, Schmidt C, Zarbock A. Perioperative acute kidney injury: an under-recognized problem. Anesth Analg 2017; **125**: 1223–32
- O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR. Incidence and associations of acute kidney injury after major abdominal surgery. *Intensive Care Med* 2016; 42: 521–30
- 98. Bihorac A, Yavas S, Subbiah S, et al. Long-term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg 2009; 249: 851–8
- 99. Chawla LS, Eggers PW, Star RA. Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371: 58–66
- 100. Silver SA, Harel Z, McArthur E, et al. Causes of death after a hospitalization with AKI. J Am Soc Nephrol 2018; 29: 1001–10
- 101. Karagozian R, Bhardwaj G, Wakefield DB, Verna EC. Acute kidney injury is associated with higher mortality and healthcare costs in hospitalized patients with cirrhosis. Ann Hepatol 2019; 18: 730–5
- 102. Argalious MY, Dalton JE, Sreenivasalu T, O'Hara J, Sessler DI. The association of preoperative statin use and acute kidney injury after noncardiac surgery. Anesth Analg 2013; 117: 916–23
- 103. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120: c179–84
- 104. Lameire NH, Levin A, Kellum JA, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney Int* 2021; 100: 516–26
- **105.** Salmasi V, Maheshwari K, Yang D, et al. Relationship between intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after noncardiac

surgery: a retrospective cohort analysis. Anesthesiology 2017; **126**: 47–65

- 106. Gregory A, Stapelfeldt WH, Khanna AK, et al. Intraoperative hypotension is associated with adverse clinical outcomes after noncardiac surgery. Anesth Analg 2021; 132: 1654–65
- 107. Maheshwari K, Turan A, Mao G, et al. The association of hypotension during non-cardiac surgery, before and after skin incision, with postoperative acute kidney injury: a retrospective cohort analysis. *Anaesthesia* 2018; **73**: 1223–8
- 108. Zacharias M, Mugawar M, Herbison GP, et al. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2013; 2013: CD003590
- 109. Kannan A, Medina RI, Nagajothi N, Balamuthusamy S. Renal sympathetic nervous system and the effects of denervation on renal arteries. World J Cardiol 2014; 6: 814–23
- **110.** Baar W, Goebel U, Buerkle H, Jaenigen B, Kaufmann K, Heinrich S. Lower rate of delayed graft function is observed when epidural analgesia for living donor nephrectomy is administered. BMC Anesthesiol 2019; **19**: 38
- 111. Parker SD, Breslow MJ, Frank SM, et al. Catecholamine and cortisol responses to lower extremity revascularization: correlation with outcome variables. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Crit Care Med 1995; 23: 1954–61
- 112. Tuman KJ, McCarthy RJ, March RJ, DeLaria GA, Patel RV, Ivankovich AD. Effects of epidural anesthesia and analgesia on coagulation and outcome after major vascular surgery. *Anesth Analg* 1991; **73**: 696–704
- 113. Suleiman MY, Passannante AN, Onder RL, Greene-Helms WF, Perretta SG. Alteration of renal blood flow during epidural anesthesia in normal subjects. Anesth Analg 1997; 84: 1076
- 114. Roberts DJ, Nagpal SK, Kubelik D, et al. Association between neuraxial anaesthesia or general anaesthesia for lower limb revascularisation surgery in adults and clinical outcomes: population based comparative effectiveness study. BMJ 2020; 371: m4104
- 115. Rooke GA, Freund PR, Jacobson AF. Hemodynamic response and change in organ blood volume during spinal anesthesia in elderly men with cardiac disease. *Anesth Analg* 1997; **85**: 99–105
- 116. Wink J, Veering BT, Aarts LPHJ, Wouters PF. Effects of thoracic epidural anesthesia on neuronal cardiac regulation and cardiac function. Anesthesiology 2019; 130: 472–91
- 117. Kirnö K, Friberg P, Grzegorczyk A, Milocco I, Ricksten SE, Lundin S. Thoracic epidural anesthesia during coronary artery bypass surgery: effects on cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics. Anesth Analg 1994; 79: 1075–81
- **118.** Olausson K, Magnusdottir H, Lurje L, Wennerblom B, Emanuelsson H, Ricksten SE. Anti-ischemic and antianginal effects of thoracic epidural anesthesia versus those of conventional medical therapy in the treatment of severe refractory unstable angina pectoris. *Circulation* 1997; **96**: 2178–82
- **119.** Gramling-Babb P, Miller MJ, Reeves ST, Roy RC, Zile MR. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. *Am Heart J* 1997; **133**: 648–55

- **120.** Lagunilla J, García-Bengochea JB, Fernández AL, et al. High thoracic epidural blockade increases myocardial oxygen availability in coronary surgery patients. Acta Anaesthesiol Scand 2006; **50**: 780–6
- 121. Richter A, Cederholm I, Fredrikson M, Mucchiano C, Träff S, Janerot-Sjoberg B. Effect of long-term thoracic epidural analgesia on refractory angina pectoris: a 10-year experience. J Cardiothorac Vasc Anesth 2012; 26: 822–8
- 122. Leslie K, Myles P, Devereaux P, et al. Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth 2013; 111: 382–90
- 123. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ* 2000; **321**: 1493
- 124. Beattie WS, Badner NH, Choi P. Epidural analgesia reduces postoperative myocardial infarction: a metaanalysis. Anesth Analg 2001; 93: 853–8
- **125.** Pöpping DM, Elia N, Van Aken HK, et al. Impact of epidural analgesia on mortality and morbidity after surgery: systematic review and meta-analysis of randomized controlled trials. *Ann Surg* 2014; **259**: 1056–67
- 126. Guay J, Choi P, Suresh S, Albert N, Kopp S, Pace NL. Neuraxial blockade for the prevention of postoperative mortality and major morbidity: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2014; 2014, CD010108
- 127. Guay J, Kopp S. Epidural pain relief versus systemic opioid-based pain relief for abdominal aortic surgery. Cochrane Database Syst Rev 2016; 2016, CD005059
- **128.** Cummings KC, Zimmerman NM, Maheshwari K, Cooper GS, Cummings LC. Epidural compared with nonepidural analgesia and cardiopulmonary complications after colectomy: a retrospective cohort study of 20,880 patients using a national quality database. *J Clin Anesth* 2018; **47**: 12–8
- 129. Scott MJ, Aggarwal G, Aitken RJ, et al. Consensus guidelines for perioperative care for emergency laparotomy Enhanced Recovery After Surgery (ERAS®) Society recommendations part 2—emergency laparotomy: intraand postoperative care. World J Surg 2023; 47: 1850–80
- **130.** Pöpping DM, Elia N, Marret E, Remy C, Tramèr MR. Protective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery: a metaanalysis. Arch Surg 2008; **143**: 990–9
- **131.** Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth 2017; **118**: 317–34
- 132. Hughes M, Yim I, Deans DAC, Couper GW, Lamb PJ, Skipworth RJE. Systematic review and meta-analysis of epidural analgesia versus different analgesic regimes following oesophagogastric resection. World J Surg 2018; 42: 204–10
- 133. Cense HA, Lagarde SM, de Jong K, et al. Association of no epidural analgesia with postoperative morbidity and mortality after transthoracic esophageal cancer resection. J Am Coll Surg 2006; 202: 395–400
- 134. Zingg U, Smithers BM, Gotley DC, et al. Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol 2011; 18: 1460–8
- **135.** Visser E, Marsman M, van Rossum PSN, et al. Postoperative pain management after esophagectomy: a systematic review and meta-analysis. *Dis Esophagus* 2017; **30**: 1–11

- **136.** Li W, Li Y, Huang Q, Ye S, Rong T. Short and long-term outcomes of epidural or intravenous analgesia after esophagectomy: a propensity-matched cohort study. PLoS One 2016; **11**, e0154380
- **137.** Kaufmann KB, Baar W, Glatz T, et al. Epidural analgesia and avoidance of blood transfusion are associated with reduced mortality in patients with postoperative pulmonary complications following thoracotomic esophagectomy: a retrospective cohort study of 335 patients. BMC Anesthesiol 2019; **19**: 162
- **138.** Odor PM, Bampoe S, Gilhooly D, Creagh-Brown B, Moonesinghe SR. Perioperative interventions for prevention of postoperative pulmonary complications: systematic review and meta-analysis. BMJ 2020; **368**: m540
- 139. McGinigle KL, Spangler EL, Pichel AC, et al. Perioperative care in open aortic vascular surgery: A consensus statement by the Enhanced Recovery After Surgery (ERAS) Society and Society for Vascular Surgery. J Vasc Surg 2022; 75: 1796–820
- 140. Chou R, Gordon DB, Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016; 17: 131–57
- 141. Vester-Andersen M, Lundstrøm LH, Møller MH, Danish Anaesthesia Database. The association between epidural analgesia and mortality in emergency abdominal surgery: a population-based cohort study. Acta Anaesthesiol Scand 2020; 64: 104–11
- 142. Wijeysundera DN, Beattie WS, Austin PC, Hux JE, Laupacis A. Epidural anaesthesia and survival after intermediate-to-high risk non-cardiac surgery: a population-based cohort study. *Lancet* 2008; **372**: 562–9
- 143. Johnson RL, Frank RD, Habermann EB, et al. Neuraxial anesthesia is associated with improved survival after

total joint arthroplasty depending on frailty: a cohort study. Reg Anesth Pain Med 2020; **45**: 405–11

- 144. Malhas L, Perlas A, Tierney S, Chan VWS, Beattie S. The effect of anesthetic technique on mortality and major morbidity after hip fracture surgery: a retrospective, propensity-score matched-pairs cohort study. *Reg Anesth Pain Med* 2019; **44**: 847–53
- 145. Brovman EY, Wallace FC, Weaver MJ, Beutler SS, Urman RD. Anesthesia type is not associated with postoperative complications in the care of patients with lower extremity traumatic fractures. Anesth Analg 2019; 129: 1034–42
- 146. Lin DY, Woodman R, Oberai T, et al. Association of anesthesia and analgesia with long-term mortality after hip fracture surgery: an analysis of the Australian and New Zealand hip fracture registry. *Reg Anesth Pain Med* 2023; 48: 14–21
- 147. Kunutsor SK, Hamal PB, Tomassini S, Yeung J, Whitehouse MR, Matharu GS. Clinical effectiveness and safety of spinal anaesthesia compared with general anaesthesia in patients undergoing hip fracture surgery using a consensus-based core outcome set and patientand public-informed outcomes: a systematic review and meta-analysis of randomised controlled trials. Br J Anaesth 2022; 129: 788–800
- 148. O'Donnell CM, McLoughlin L, Patterson CC, et al. Perioperative outcomes in the context of mode of anaesthesia for patients undergoing hip fracture surgery: systematic review and meta-analysis. Br J Anaesth 2018; 120: 37–50
- **149.** Admiraal M, Marhofer P, Hopkins PM, Hollmann MW. Peripheral regional anaesthesia and outcomes: a narrative review of the literature from 2013 to 2023. Br J Anaesth 2024; **132**: 1082–96
- **150.** Su J, Soliz JM, Popat KU, Gebhardt R. Complications of postoperative epidural analgesia for oncologic surgery: a review of 18,895 cases. *Clin J Pain* 2019; **35**: 589–93

Handling Editor: Kate Leslie